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Pulmonary hypertension (PH) is a heterogeneous condition with classification based on shared pathophysiological characteristics.  There is a paucity of literature reflecting the spectrum of disease across the 5 diagnostic groups encountered at a specialist referral centre in the era of the widespread availability of targeted pulmonary vascular therapy.  

The first part of this thesis focuses on the ASPIRE registry; a large registry of contemporary, consecutive, treatment-naïve patients identified at a specialist PH centre using a catheter-based approach.  Uniquely, the ASPIRE registry compares the natural history of all forms of PH, providing new and novel insights into the natural history of rare groups such as pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension and more common but less well studied forms such as PH associated with left heart disease and lung disease where the role of targeted therapies is not clear.  This registry demonstrates that outcomes and characteristics differ between and within PH diagnostic groups. In addition, the current system of diagnostic classification in PH has prognostic value even when adjusted for age and haemodynamic severity emphasizing the importance of systematic evaluation and precise classification.  

The second part of this thesis focuses on patients in group 3; pulmonary hypertension associated with lung disease, concentrating particularly on chronic obstructive pulmonary disease (COPD) and emphysema, the most common type of lung disease associated with PH.  The characteristics of patients with severe PH associated with COPD (PH-COPD) differed from those with mild to moderate PH-COPD despite similar degrees of emphysema on CT scan.  Survival in PH-COPD was poor and this study identified independent predictors of outcome.  Patients with severe PH-COPD share certain characteristics with PAH such as the degree of haemodynamic severity and right ventricular impairment.  This leads to the question of whether therapies frequently prescribed in PAH should be considered for this group.  In the largest cohort yet studied, a minority of patients with severe PH-COPD demonstrated objective evidence of improvement with compassionate treatment with targeted pulmonary vascular therapies and where there was evidence of clinical benefit, patients demonstrated superior survival. This data suggests that further evaluation of targeted therapies is warranted in patients with severe PH-COPD. 

In conclusion, retrospective review of this cohort of patients has provided a detailed comparison of characteristics between and within PH diagnostic groups, assessed prognostic markers and provided insights into the effects of targeted pulmonary vascular treatment in severe PH-COPD.  This underscores the importance of thorough assessment and accurate classification to ensure appropriate management and prudent use of costly therapies.  This registry also provides detailed phenotypic information which may be helpful when defining entry criteria for clinical trials.
 
The characterization of this patient cohort has also lead to a number of publications from collaborative projects in the Academic Unit of Radiology.
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1.1	The normal pulmonary circulation		






1.2.1	Definition of pulmonary hypertension

Pulmonary Hypertension (PH) is a haemodynamic and pathophysiological condition defined as a mean pulmonary artery pressure ≥ 25mmHg at rest measured at right heart catheter (RHC).[5]  At rest, a normal mPAP is considered to be <20mmHg, leaving a group with mPAP between 21 and 24mmHg, the significance of which is unclear. ADDIN EN.CITE [6] 

In the past, the definition of PH also included pulmonary hypertension on exercise defined as mPAP ≥ 30mmHg on exercise but published data to support this as a disease state similar to PH at rest is lacking.  Moreover, normal individuals may reach mPAP >30mmHg on exercise.[1]  Therefore no definition for PH on exercise is currently available. ADDIN EN.CITE [6] 
1.3	Clinical classification of pulmonary hypertension

In 1973, the first World Health Organisation (WHO) symposium[7] defined PH and identified primary disease without known cause and other patients with PH secondary to underlying medical conditions.  The histological similarities between PH of unknown cause and some forms of PH associated with other conditions were increasingly recognised. ADDIN EN.CITE [8, 9]  Also in the wake of new therapeutic options, precise diagnostic classification has become increasingly important to allow accurate prognostication and to facilitate randomised controlled trials (RCTs) of drugs and ultimately treatment choice.  Thus, in 2008 at the Fourth WHO symposium, the algorithm for clinical classification in pulmonary hypertension grouped into categories diseases that shared common underlying pathological mechanisms, disease course and response to treatment and produced the Updated Clinical Classification of Pulmonary Hypertension (Dana point 2008). ADDIN EN.CITE [10]  This identifies five major forms: Group 1 - Pulmonary Arterial Hypertension (PAH), Group 2 – PH associated with left heart disease (PH-LHD), Group 3 – PH associated with lung disease (PH-Lung), Group 4 – Chronic thromboembolic pulmonary hypertension (CTEPH), and a miscellaneous group 5 (PH-miscellaneous). ADDIN EN.CITE [10]  (Figure 1)  

The classification takes into account whether the main pathological change is in the pulmonary arterial bed (precapillary PH / PAH) as in Groups 1, 3, 4 and 5 or in the pulmonary venous circulation (non-precapillary PH) as in Group 2.  Classically, the haemodynamic features differ between the two groups with precapillary PH having a pulmonary capillary wedge pressure (PCWP) ≤ 15mmHg and a PVR >240 dynes.	

Throughout this thesis, PAH will be used exclusively when discussing patients in group 1 and the term PH may refer to patients in groups 2 to 5 and to all groups collectively.  This thesis refers to adult patients (>16years of age).  The definitions used in this thesis refer to the 2008 classification which was in place at the time of this study and was superseded in 2013 by a further updated clinical classification of pulmonary hypertension produced at the 5th World Symposium. ADDIN EN.CITE [13] 


Figure 1 The Updated Clinical Classification of Pulmonary Hypertension (Dana Point, 2008)  ADDIN EN.CITE [10]​[1]​





1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)
1.2.3. Unknown
1.3. Drug- and toxin-induced
1.4. Associated with
1.4.1. Connective tissue diseases
1.4.2. Human Immunodeficiency Virus infection
1.4.3. Portal hypertension
1.4.4. Congenital heart diseases
1.4.5. Schistosomiasis
1.4.6. Chronic haemolytic anaemia
1.5 Persistent pulmonary hypertension of the newborn

11=. Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis






3. Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities

4. Chronic thromboembolic pulmonary hypertension (CTEPH)

5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis


1.3.1 The disease burden of pulmonary hypertension

Overall the prevalence of severe PAH in Western Europe is estimated to be 15 cases/million adult inhabitants ADDIN EN.CITE [11] and United Kingdom national audit data recognised 46 cases of PAH in adults per million population.[12] It is noteworthy that although PAH is considered a rare disease, conditions that may be associated with PH are highly prevalent throughout the world and include sickle cell disease, infection with schistosomiasis or human immunodeficiency virus (HIV), cirrhosis of the liver, lung disease and left-sided heart disease. 
1.4	Diagnostic groups: Clinical definitions, characteristics	and epidemiology
1.4.1 Group 1 Pulmonary Arterial Hypertension

PAH can occur in the absence of predisposing conditions, now called idiopathic PAH (IPAH) or in association with congenital heart disease (PAH-CHD) or a number of disparate systemic diseases including connective tissue disease (PAH-CTD), in particular systemic sclerosis (PAH-SSc).  In these patients, a devastating pulmonary arteriopathy with structural change and vasoconstriction in the pulmonary muscular arteries and arterioles leads to a progressive increase in PVR resulting in right heart failure and early death.  
1.4.1.1 Idiopathic, familial and drug or toxin induced PAH
It is usual practice for drug induced and heritable PAH to be grouped with IPAH as there are no distinctive features except that heritable PAH may present with less severe exercise impairment. ADDIN EN.CITE [11, 14]  In addition, genetic testing in patients with sporadic IPAH has shown a high prevalence of genetic mutations and heritable PAH may be underdiagnosed if ancestral lineage is not appreciated.[15]  The term heritable PAH includes sporadic IPAH with genetic mutations and familial cases with or without known genetic mutations. ADDIN EN.CITE [6]  Genetic testing is not mandated in IPAH because presently the presence or absence of genetic mutations does not alter management. 

Anorexigen associated PAH is related to the use of aminorex and fenfluramine derivatives ADDIN EN.CITE [16-21] which were withdrawn in the USA and subsequently most other markets around the world in 1997.  Other drugs known or suspected to be associated with the development of PAH are stimulants such as cocaine, amphetamine and methamphetamine. ADDIN EN.CITE [6, 22]  More recently, the tyrosine kinase inhibitor Dasatinib, used to treat haematological malignancies has also been associated with cases of PAH. ADDIN EN.CITE [23] 
1.4.1.2 PAH associated with connective tissue disease
Connective tissue diseases (CTD) are a range of disorders characterised by vascular, inflammatory and fibrotic manifestations in many organs including the skin, kidney and lung. PAH is a major source of morbidity and mortality for patients with CTDs.[24] 

Systemic sclerosis or scleroderma (SSc) is a progressive, multisystem disorder characterised by the presence of fibrosis and excessive collagen deposition in the skin, microvascular endothelial dysfunction and varying degrees of internal organ involvement.[25]  Based on the extent and distribution of skin involvement, SSc is subcategorised into limited cutaneous (skin lesions restricted to the distal limbs ± face/neck) or diffuse cutaneous forms. In SSc, more then 10% of patients develop PH ADDIN EN.CITE [26] ADDIN EN.CITE  and PAH is known to have a major impact on survival. ADDIN EN.CITE [27-31]  Therefore, it is recommended that PH is identified early by means of a systematic echocardiography-based screening programme and the benefit of this approach has been demonstrated in the multicentre, DETECT study where the majority of patients had mild disease at diagnosis of PAH. ADDIN EN.CITE [6, 32, 33]  The Sheffield CTD screening programme was implemented in our region from 2002 onwards and screening recommendations are shown in figure 2.  

Connective tissues diseases other than SSc may be associated with PAH but less frequently[34] and there is a relative paucity of literature regarding these subgroups.  These include systemic lupus erythematosis (SLE), sjogren’s syndrome, rheumatoid arthritis (RA), dermatomyositis and mixed connective tissue disease (MCTD) which is an overlap condition with features of SSc, polymyositis and SLE from which patients may eventually differentiate into a definable CTD or remain diagnosed as MCTD as a distinct entity. ADDIN EN.CITE [35, 36]






Figure 2 The Sheffield pulmonary vascular disease unit CTD screening protocol

This screening protocol advocates annual echocardiogram (ECHO) and assessment of diffusion capacity of the lung for carbon monoxide (TLco) in SSc and MCTD and baseline ECHO and TLco in SLE with the aim of promoting referral of patients with less advanced disease.  Patients with other CTDs such as RA are screened only in the presence of symptoms.  Specialist referral is advised if tricuspid gradient (TG) is >40mmHg or TG 30-40mmHg with TLco<50% unexplained dyspnoea.​[3]​





In CTD, the pulmonary circulation may be directly involved or PH may occur in association with interstitial lung disease where survival is inferior to that of isolated PAH although haemodynamic disturbances are similar to those seen in isolated PAH. ADDIN EN.CITE [29] 

Furthermore, patients with CTD are prone to systemic hypertension and ischaemic heart disease. ADDIN EN.CITE [38]  In addition, particularly in SSc, primary cardiac involvement (often subclinical) is increasingly recognised with a diffuse microangiopathy of the myocardium leading to myocardial fibrosis. ADDIN EN.CITE [39-41]   Therefore PH may be associated with left heart disease in patients with CTD and these patients are more likely to be selected for extensive investigation of PH than patients with PH-LHD without underlying CTD due to the grave consequences of failing to diagnose and treat PAH in patients with CTD.
1.4.1.3 PAH associated with Human Immunodeficiency Virus 	   infection
In patients with HIV, early literature reported approximately 1 in 200 patients develop PAH[42] but there is also evidence that therapy with antiretroviral drugs improves PAH-related outcomes in patients with HIV. ADDIN EN.CITE [43, 44]  PAH is an independent risk factor for mortality in HIV infected individuals ADDIN EN.CITE [44] and should be considered in patients with HIV who are dyspnoeic but screening for PAH in patients with HIV is not routine in the United Kingdom[32].

1.4.1.4 Porto-pulmonary hypertension
In patients with portal hypertension, the prevalence of PAH is above 5%. ADDIN EN.CITE [45, 46]  Classically patients with porto-pulmonary hypertension exhibit higher cardiac output (CO) and lower PVR than IPAH.  Liver transplant in the setting of severe porto-pulmonary hypertension carries increased risk of perioperative mortality and reduced quality of life post-operatively ADDIN EN.CITE [46, 47] and therefore screening for and medical treatment of PAH is advised prior to transplant listing.[48]
1.4.1.5 PAH associated with congenital heart disease
PAH may occur with a multitude of congenital heart defects but defects in the ventricular or atrial septum are the most common.  In a large cohort of patients with congenital heart disease (CHD) ADDIN EN.CITE [49], the prevalence of PAH associated with septal defects was 6%, with half of these patients with PAH meeting the definition of Eisenmenger’s syndrome; a congenital heart defect with initially large systemic-to-pulmonary shunt, which in turn induces severe pulmonary vascular disease and PAH, resulting in reversal of the shunt direction and central cyanosis. ADDIN EN.CITE [50] 









Eisenmenger’s Syndrome	Includes all systemic-to-pulmonary shunts due to large defects leading to a severe increase in PVR and resulting in a reversed (pulmonary-to-systemic) or bidirectional shunt. Cyanosis, erythrocytosis and multiple organ involvement are present.
PAH associated with systemic-to-pulmonary shunts	In these patients with moderate to large defects, the increase in PVR is mild to moderate, systemic-to-pulmonary shunt is still largely present and no cyanosis is present at rest
Pulmonary arterial hypertension with small defects	In cases with small defects (usually VSD <1cm or ASD <2cm of effective diameter assessed by echocardiography) the clinical picture is very similar to IPAH.
Pulmonary arterial hypertension after corrective cardiac surgery	In these cases, congenital heart disease has been corrected but PAH is either still present immediately after surgery or has recurred several months or years after surgery in the absence of significant post-operative residual congenital lesions or defects that originate as a sequela to previous surgery
Abbreviations PVR; pulmonary vascular resistance, ASD; atrial septal defect, VSD; ventricular septal defect

In adults with Eisenmenger’s syndrome, despite similar elevations in mPAP, right atrial pressure (RAP) and CO are better preserved than in IPAH due to the “training effect” of longstanding right ventricular hypertension.[51]  Prior to the availability of modern therapies, 3 year survival in adult patients with Eisenmenger’s syndrome at 77% was superior to that of patients with IPAH at 35%.[51]
1.4.1.6 PAH in association with chronic haemolytic anaemia
Chronic haemolytic anaemia may result in PAH due to the high rate of nitric oxide consumption by cell-free haemoglobin in chronic haemolysis.[52]  Chronic haemolytic anaemias include sickle cell disease ADDIN EN.CITE [53], thalassaemia, hereditary spherocytosis and microangiopathic haemolytic anaemia.  Both chronic anaemia and chronic liver disease are high cardiac output states and increased pulmonary blood flow can increase mPAP but without an elevated PVR this is not considered true PAH. 
1.4.1.7 Pulmonary capillary wedge pressure in IPAH

The haemodynamic features of IPAH are those of precapillary disease and include mPAP ≥ 25 mmHg and a PCWP ≤ 15mmHg in the setting of normal or reduced CO. ADDIN EN.CITE [10]  However, increasingly IPAH is seen in patients of greater age ADDIN EN.CITE [11, 54] and with a greater burden of comorbid conditions. ADDIN EN.CITE [55]  Elevation in PCWP may occur particularly in women as left ventricular diastolic stiffness increases with age and therefore, elderly patients with suspected IPAH may not meet strict haemodynamic criteria for the diagnosis due to elevated PCWP.[56]  Expanded haemodynamic criteria for IPAH allowing a PCWP ≤ 18mmHg have been suggested but this is a group where further study is required. ADDIN EN.CITE [55]  Interestingly survival in patients with IPAH and an elevated PCWP appears similar to that seen in patients with PCWP ≤ 15mmHg[57]. 
1.4.1.8 Group 11 Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis
Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary haemangiomatosis (PCH) are thought to represent part of the same spectrum as PAH.  In PVOD, the pulmonary venules and veins are occluded by fibrous tissue and with extensive medial thickening in the vein the vessel becomes arterialised, while PCH is characterised by local capillary proliferation.[8]  In both PVOD and PCH, characteristic changes seen on lung imaging are crucial to the diagnosis. ADDIN EN.CITE [58, 59]  The distinction of these conditions from precapillary PAH is crucial as therapy with pulmonary vasodilators may precipitate pulmonary oedema in this rare diagnostic subgroup. ADDIN EN.CITE [60, 61]
1.4.2 Group 2 Pulmonary hypertension in association with left heart disease

In this group, back pressure across the pulmonary vascular bed due to left atrial hypertension requires an increase in pulmonary artery pressure (PAP) to maintain an adequate driving force.  Left atrial hypertension may occur in systolic or diastolic left ventricular or aortic/mitral valvular heart disease.  The classical haemodynamic description is mPAP ≥ 25mmHg and a PCWP >15mmHg.  Although PCWP may be elevated at RHC, PCWP is prone to technical difficulties resulting in inaccurate results and in addition, in many patients with left ventricular diastolic dysfunction, PCWP may be normal.[62]  Left heart failure is a common cause of PH and the presence of PH in patients with heart failure is associated with greater likelihood of hospitalisation and death. ADDIN EN.CITE [63, 64]

Left ventricular diastolic dysfunction or heart failure with preserved ejection fraction is one of the most challenging differential diagnoses of IPAH.  PCWP may be at the upper end of the normal range or slightly elevated.  Diastolic dysfunction of the left ventricle should be suspected in patients with left atrial enlargement, atrial fibrillation and other risk factors such as diabetes mellitus, older age and systemic hypertension. ADDIN EN.CITE [6]  ADDIN EN.CITE  Echocardiography may also suggest diastolic dysfunction with evidence of elevated left ventricular filling pressures and left ventricular hypertrophy particularly if concentric. ADDIN EN.CITE [65] 

For the majority of patients with PH-LHD, the PVR is within the normal range and PH is “passive”.  However, a minority develop intrinsic changes in the pulmonary circulation with obstructive remodelling of the pulmonary arteries and vasoconstriction.  In these patients PVR may become elevated, a situation termed “reactive” PH-LHD, where the degree of PAP elevation may be out of proportion to the severity of the underlying left heart disease. ADDIN EN.CITE [6, 63] ADDIN EN.CITE 
1.4.3 Group 3 Pulmonary hypertension in association with lung disease or hypoxia

This group is discussed in detail in chapter 2
1.4.4	Group 4 Chronic Thromboembolic Pulmonary Hypertension
CTEPH is another form of pre-capillary PH and includes patients with multiple, chronic thrombotic occlusions of the proximal or distal pulmonary vasculature associated with vascular remodelling even in non-occluded areas of the pulmonary microcirculation. ADDIN EN.CITE [6, 66]  CTEPH may occur in up to 3.8% of patients following an acute pulmonary embolism (PE). ADDIN EN.CITE [67] ADDIN EN.CITE   However, a significant number of patients may present with CTEPH without a previously diagnosed episode of venous thromboembolism.[68]  The United Kingdom national incidence of CTEPH is reported to be 1.75 cases per year per million individuals. ADDIN EN.CITE [69] ADDIN EN.CITE   Historically, outcomes associated with CTEPH were poor. ADDIN EN.CITE [70, 71]  More recently, Condliffe et al showed improved survival in the modern era of targeted pulmonary vascular therapy and surgical treatment by pulmonary endarterectomy (PEA) for suitable patients with proximal (surgically accessible) disease. ADDIN EN.CITE [69] ADDIN EN.CITE 
1.4.5	Group 5 Pulmonary Hypertension with unclear 	 multifactorial mechanisms
This final group classifies patients who do not fall under groups 1-4.  Group 5 contains uncommon forms of PH and there is little literature about many of the diagnostic subgroups in this group.  These heterogeneous conditions have multifactorial or uncertain pathogenetic mechanisms including inflammation, extrinsic compression and mechanical obstruction of the pulmonary vasculature. 

However, one notable subgroup is PH in association with sarcoidosis (PH-sarcoidosis).  Sarcoidosis is a multisystem disease of unknown aetiology characterised by tissue infiltration with non-caseating granulomata.[72]  Some studies have demonstrated a prevalence of PH in sarcoidosis above 5% ADDIN EN.CITE [73] and in patients with sarcoidosis listed for lung transplantation above 70%.[74]  In sarcoidosis, PH is commonly the result of left heart dysfunction due to myocardial involvement or the result of obliteration of the pulmonary vasculature caused by pulmonary fibrosis.  However, PH may also occur in the absence of pulmonary fibrosis due to granulomatous infiltration of the pulmonary arterioles resulting in a sarcoid vasculopathy or due to extrinsic compression of pulmonary arteries by enlarged mediastinal lymph nodes. ADDIN EN.CITE [75]  Hence, PH-Sarcoidosis is not classified in group 3 as there are multiple mechanisms that may result in PH in patients with sarcoidosis.  In patients with PH-sarcoidosis in the United Kingdom, access to therapy for PAH is now available and small case series indicate a benefit with targeted pulmonary vascular therapy.[76].
1.5 Pathogenesis of pulmonary hypertension
	
A detailed description of the pathological mechanisms that play a role in PH is beyond the scope of this thesis.  In brief, in PAH many mechanisms culminate in dysregulation of pulmonary artery smooth muscle cells causing the histological changes seen in PAH.  These include mutations in bone morphogenetic protein receptor type II (BMPR-2) gene, various polymorphisms in 5-hydroxytryptamine transporter (5-HT) and perivascular inflammation. ADDIN EN.CITE [77, 78]  Despite substantial increases in our understanding of the pathogenesis of PAH over recent years, the exact process that initiates the pathological changes in IPAH is unknown. 

In PAH, the distal pulmonary arteries (<500µm in diameter) are particularly affected undergoing luminal obliteration.  Vascular remodelling involves hypertrophy at intimal, medial and adventitial levels with associated fibrotic change, perivascular inflammation and the formation of plexiform​[4]​ and thrombotic lesions.  This is driven by hypoxia, inflammation and, as the lumen narrows, shear stress. ADDIN EN.CITE [8, 79]  Additionally, there is a reduction in the total number of blood vessels in the lung in PH. ADDIN EN.CITE [80]  Although the pathological changes are limited to the vessel wall, uncontrolled proliferation is directed towards the vessel lumen. These mechanisms lead to reductions in the pulmonary vessel radius, which result in increased resistance to flow requiring a corresponding increase in PAP.  In PAH, the pulmonary veins and venules are classically unaffected, hence the term “precapillary” disease.  Most severe forms of PAH are pathologically indistinguishable.

In PH-LHD the pulmonary veins, capillaries and lymphatic vessels become dilated.  Distal pulmonary arteries may be affected by medial hypertrophy and intimal fibrosis. ADDIN EN.CITE [81]  In PH-Lung, medial hypertrophy and intimal proliferation may occur but also parenchyma diseases such as interstitial fibrosis and emphysema may be associated with destruction of the pulmonary microcirculation.

In CTEPH, organised thrombi attach to the medial layer of the pulmonary arteries causing mechanical obstruction to flow.  These thrombi may recanalise producing bridge septations and colander-like lesions.[8]  In addition, a distal small-vessel vasculopathy develops with histological changes indistinguishable from those encountered in IPAH.[82]  These histological changes are seen in both occluded and non-occluded vascular beds ADDIN EN.CITE [82, 83] and are thought to reflect the effects of sheer stress, inflammation, pressure and the release of cytokines and vasculotrophic mediators. 
1.5.1 The role of the right ventricle 
In health, the right ventricle achieves the same stroke volume as the left ventricle but requiring only a fraction of the work due to the low resistance of the pulmonary vasculature bed. 

In PAH, vasoconstriction and vascular remodelling lead to a relentless increase in PVR.  Increased right ventricular afterload leads to pathological remodelling, right ventricular failure and decreased right ventricular stroke volume, ultimately leading to a progressive reduction in CO. ADDIN EN.CITE [84] 





The theoretical progression of pulmonary vascular disease and the subsequent effect on right ventricular function from normal physiological conditions (top) to severe pulmonary vascular remodelling and subsequent right ventricle failure (below).  Reproduced with permission – Circulation 2009.[85] RV; right ventricle, LV; left ventricle PA; pulmonary artery, CO; cardiac output, PVR; pulmonary vascular resistance.

Initially, the right ventricle adapts to increased pressure with hypertrophy (figure 3).  However, the capability of the right ventricle to sustain long term pressure overload is only part of the story.  It is postulated that the abnormal pulmonary circulation in PAH releases mediators that interfere with the adaptive processes in the right ventricle and hypertrophy becomes maladaptive. ADDIN EN.CITE [86] ADDIN EN.CITE   The right ventricle eventually enters a vicious cycle of dilation, compromised right ventricular perfusion and contractility leading to further dilation resulting in right ventricle failure.[87]  The exact pathophysiological mechanisms involved in this process remain unresolved.[87]  In addition, there are conditions where diffuse myocardial involvement contributes to a disproportionate reduction in right ventricular performance such as sarcoidosis and SSc. ADDIN EN.CITE [88, 89]  Also, electrical instability due to changes in right ventricular structure may lead to arrhythmias in patients with PH.[90]

Patient outcomes are primarily dependent on the response of the right ventricle to increased afterload. ADDIN EN.CITE [91-94]  Markedly elevated RAP and reduced stroke volume index in patients dying from PH confirm right heart failure as the resulting cause of death. ADDIN EN.CITE [91]  In addition, right ventricular failure is potentially reversible with sustained recovery of right ventricular function seen following successful PEA ADDIN EN.CITE [95] and lung transplantation. ADDIN EN.CITE [96]  Right ventricular failure independently predicts poor outcome in many conditions including left heart disease ADDIN EN.CITE [97], PE ADDIN EN.CITE [98], COPD[99], and PH ADDIN EN.CITE . ADDIN EN.CITE [84]  Change in right ventricular stroke volume during PH treatment measured by magnetic resonance imaging (MRI) may be useful in conjunction with haemodynamic parameters to assess clinical progress. ADDIN EN.CITE [84] There is also emerging evidence that pulmonary vascular therapy improves cardiac function and reduces hypertrophy in right hearts exposed to sustained pressure overload. ADDIN EN.CITE [100] 
1.6 Clinical manifestations of pulmonary hypertension 	
The classic presenting symptoms in patients with PH include exertional dyspnoea, chest pain and syncope.[101]  Many patients also exhibit lethargy.  Symptoms and clinical signs may be subtle.  Delayed diagnosis represents a significant challenge in PH because delay in therapy initiation potentially worsens patient outcomes. ADDIN EN.CITE [18, 102]  The symptoms stem from inability to increase CO adequately on exercise.[103]  As right ventricular failure develops with increased right ventricular end-diastolic pressure, patients become fluid overloaded developing peripheral oedema and ascites. 
1.7 The Investigation of suspected pulmonary hypertension

Clinical history and examination may provide many clues to the diagnostic subtype and severity of PH.  For patients in whom PH is suspected, this is followed by extensive diagnostic testing aimed at confirming the presence of PH, eliciting any underlying cause and evaluating the degree of functional and haemodynamic impairment. ADDIN EN.CITE [10, 104] 

Basic investigations include electrocardiogram (ECG), chest x-ray, blood tests and pulmonary function testing.  These tests are insufficiently sensitive and specific to confirm or refute a diagnosis of PH and may not correlate well with disease severity but form part of the clinical picture. ADDIN EN.CITE [105, 106]  In 80-90% of patients with PH chest x-ray and/or ECG are abnormal at diagnosis.[107]

Patients then undergo more detailed assessment.  Both transthoracic and transoesophageal ECHO and MRI have a role in defining cardiac anatomy and function in PH.  The gold standard investigation to confirm the diagnosis is RHC to define the pulmonary haemodynamics.  Computed tomography (CT) scanning also plays an important role in assessing the lung parenchyma and evaluating pulmonary, cardiac and major vessel dimensions.  In conjunction with magnetic resonance pulmonary angiography (MRA) and lung perfusion scanning, CT is integral to the evaluation of chronic thromboembolic disease. 
1.7.1	Electrocardiography
ECG allows assessment of heart rate and rhythm and may provide supportive evidence of PH such as demonstrating right axis deviation, right ventricular hypertrophy or strain.[101]  ECG features of right heart impairment in IPAH have been shown to independently predict of survival.[108]
1.7.2	Chest radiograph
Chest x-ray may reveal cardiomegaly or central pulmonary artery dilation with peripheral pruning of vessels.  However chest x-ray may be normal in milder cases.  Pleural effusions are frequently seen in patients with right heart failure.[109]  Chest x-ray also facilitates the initial assessment of lung parenchyma. 
1.7.3 Pulmonary Function Testing & Arterial Blood Gases
Evaluation of pulmonary function is important both in the assessment of underlying lung disease and precapillary pulmonary hypertension.  Pulmonary function testing includes spirometry recording forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) and measurement of the single-breath lung diffusing capacity of carbon monoxide (TLco) also known as transfer factor. Patients with IPAH typically have a reduced TLco and even in the absence of another lung disease may have spirometric evidence of peripheral airway obstruction.[110]  In patients with CTEPH, TLco is also often reduced  and spirometry usually normal although some patients with CTEPH will have mildly restrictive spirometry thought to be related to scarring from earlier pulmonary infarction.[111]  TLco is a valuable prognostic marker in PAH. ADDIN EN.CITE [112, 113] 

The presence of obstructive sleep apnoea (OSA) or obesity hyperventilation syndrome should also be excluded by overnight pulse oximetry.[114]

Patient with PH are often hypoxaemic.  In IPAH, ventilation-perfusion matching remains preserved with hypoxaemia a consequence of low mixed venous oxygen concentration (SvO2) due to poor CO. ADDIN EN.CITE [115, 116]  In PAH-CHD-Eisenmenger’s, hypoxaemia is due to intracardiac right-to-left shunt.  In patients with severe PH-lung, pulmonary gas exchange is also reduced by respiratory disease which may in combination with PH lead to marked hypoxaemia.  Arterial blood gases (ABGs) assess arterial oxygen (PaO2) and carbon dioxide (PaCO2) tension and provide an invasive and often more accurate assessment of hypoxaemia.  ABGs are central to patient assessment for supplemental oxygen therapy.
1.7.4 Blood tests

A panel of blood tests are recommended to assess clinical status and uncover the underlying cause of PH.  These include renal, liver and thyroid function tests, full blood count, HIV serology, thrombophilia testing and an immunology screen particularly focused on autoantibodies typically positive in CTD such as anti-centromere antibodies in limited cutaneous SSc. ADDIN EN.CITE [6] 
1.7.4.1 Biomarkers

Several candidates have been proposed as biomarkers that correlate with haemodynamics and may be useful in PH in combination with other parameters for diagnostic screening, prognostication and evaluating response to therapy.  These include brain natriuretic peptide, troponin, uric acid, endothelin 1 and osteoprotegerin. ADDIN EN.CITE [117-123]  However, the value of these parameters remains to be tested in prospective studies. (Appendix 1) 
1.7.5	Doppler echocardiogram 

RHC remains the gold standard for providing definitive haemodynamic measurements ADDIN EN.CITE [6] ADDIN EN.CITE  but is invasive with inherent risks and so unsuitable as a routine screening test.  ECHO is recommended as the initial non-invasive investigation to evaluate patients for evidence of PH and the modified Bernoulli equation​[5]​ is used to estimate right ventricular systolic pressure (RVSP) by measuring right atrial pressure and the peak velocity of the tricuspid regurgitant jet. In the absence of pulmonary outflow tract obstruction, RVSP is considered equivalent to systolic pulmonary artery pressure (sPAP).  

The utility of ECHO for this purpose was first validated in the 1980s ADDIN EN.CITE [124-128] ADDIN EN.CITE  and work in unselected cardiovascular patients demonstrated that well-trained personnel can obtain PAP in >95% of ECHOs performed.[126]  

While ECHO is a useful tool in the initial evaluation of cardiac chamber size and function, due to reliability issues with over and under estimation of sPAP reported, the use of ECHO in screening particularly mild or asymptomatic patients can be troublesome. ADDIN EN.CITE [129-132]  ECHO is however central to pragmatic screening programmes and, particularly in subjects where there is high index of suspicion of PH, such as patients with SSc, correlation with RHC pressures are reasonable.[133] 

The development of novel, more complex ECHO techniques provide hope that in future ECHO can be more sensitive and specific in the detection of PH.
Measurement of tricuspid annular plane systolic excursion (TAPSE) has been shown to correlate with right ventricular function and survival. ADDIN EN.CITE [134, 135]  Also, tissue doppler ADDIN EN.CITE [136, 137] and speckle tracking strain imaging ADDIN EN.CITE [137-140] show promise for detailed ECHO evaluation of right ventricular function.  PVR may also be estimated from Doppler measurements. ADDIN EN.CITE [141, 142]
 
ECHO also provides detailed information about cardiac structure and function thus assessing right heart dilation, right ventricular hypertrophy, left atrial dilation, left ventricular systolic and diastolic function, the competence of the valves and the presence of a pericardial effusion or congenital heart defects.  
1.7.6	Right heart catheterisation		

RHC is the gold standard investigation for diagnosis of PH, assessment of disease severity and testing pulmonary vasoreactivity.  At RHC, pressure in the right heart and pulmonary artery are measured directly and the output of the right ventricle is measured indirectly​[6]​. Thus RHC determines many prognostic parameters including RAP, CO and mPAP. ADDIN EN.CITE [91]  In addition, the tip of the catheter is wedged into the peripheral part of the pulmonary artery to measure the PCWP.  This allows evaluation of pulmonary venous pressures.  PCWP equates to left atrial pressure and therefore, in the absence of mitral valve disease, left ventricular end-diastolic pressure (LVEDP).  The definition of PAH as discussed in section 1.2.1 requires PCWP ≤15mmHg because studies of PCWP and LVEDP have suggested that 14mmHg is within 2 standard deviations of the mean normal PCWP ADDIN EN.CITE [143, 144].  This highlights that a PCWP of 14mmHg is still not “normal”. 

As PCWP is equivalent to left atrial pressure, PVR may be calculated via the following equation (Wood Units):
PVR= 		mPAP-PCWP							        CO
where mPAP is mean pulmonary artery pressure, PCWP, pulmonary capillary wedge pressure and CO is cardiac output.

Further parameters assessed at RHC are cardiac index (CI) and mixed venous oxygen saturation (SvO2).  CI expresses cardiac output per minute divided by body surface area.  SvO2 measures the percentage of oxygen bound to haemoglobin in blood returning to the right side of the heart.

An acute vasodilator challenge should be administered with either intravenous prostanoid or inhaled nitric oxide at the time of RHC to identify the small group (~5%) of patients with IPAH who are likely to benefit from long term treatment with calcium channel blockers (CCB). ADDIN EN.CITE [6, 11, 145, 146]  Vasoreactivity testing is contraindicated in patients with PAH with significant venous or capillary involvement due to the risk of precipitating pulmonary oedema.

When performed in pulmonary vascular specialist centres for the investigation of pulmonary hypertension, morbidity (~1%) and mortality (<0.1%) rates associated with RHC procedures are low. ADDIN EN.CITE [147]


1.7.7 Magnetic resonance imaging parameters in PH		

Cardiovascular MRI has emerged as a standard for the assessment of right ventricular function and characteristics of the pulmonary vascular bed.[148]  When compared to ECHO, MRI offers greater accuracy, lower operator dependence and greater interstudy reproducibility. ADDIN EN.CITE [149]  MRI allows imaging of both the right ventricle and the lungs in one non-invasive modality and is validated for monitoring patients on therapy.[148]  Increased right ventricular end diastolic volume is an important prognostic marker and reflects the degree of right ventricular overload and failure. ADDIN EN.CITE [84]

For MRA, Gadolinium contrast is injected via a peripheral vein in order to obtain a detailed three dimensional pulmonary angiogram.  In PAH, MRA classically demonstrates loss of peripheral vascularity and reduced branching pattern (“pruning”).  MRA is also integral to diagnosis and operative planning in CTPEH.  

Lung perfusion MRI has high sensitivity equivalent to perfusion scintigraphy in diagnosing CTEPH but does not require ionising radiation, making it an attractive initial imaging modality to assess patients with suspected CTEPH.[150]
1.7.8 Computerised tomography scan
CT scans provide detailed morphological assessment of lung parenchyma, cardiac morphology and the pulmonary vasculature.  CT pulmonary angiogram (CTPA) allows detailed assessment for chronic thromboembolic disease with the evaluation of clot burden and assessment of surgical accessibility. ADDIN EN.CITE [151]  Although a negative CTPA does not fully exclude the diagnosis of CTEPH, the advent of multi-row detector CT scans has increased diagnostic accuracy.[150]  In addition, enlargement of the main pulmonary artery to greater than the accompanying aorta or >3.32cm measured at the level of pulmonary artery bifurcation is suggestive of PH[152], with the caveat that in parenchymal lung disease, main pulmonary artery dilatation may occur without underlying PH.[153]

CTPA can also identify inferior vena cava and hepatic reflux of contrast indicative of right heart dysfunction and tricuspid regurgitation. ADDIN EN.CITE [154]  CTPA aids assessment of right heart chamber size and hypertrophy of the right ventricle and its outflow tract.  CT scan of the thorax also visualises pleural and pericardial effusions, signs of chronic liver disease and may reveal enlarged bronchial arteries which commonly occur in CTEPH and PAH-CHD and may be a source of haemoptysis.[155]

High resolution CT (HRCT) scan affords detailed views of the lung parenchymal and enables the detection of fibrotic lung diseases and emphysema.  
 1.7.9 Isotope Perfusion lung scan					

Perfusion lung scan (Q scan) has greater sensitivity than CTPA for the detection of CTEPH and thus remains the screening method of choice for CTEPH, which should be excluded in all patients with PH. ADDIN EN.CITE [156]  A completely normal Q scan effectively excludes CTEPH ADDIN EN.CITE [5, 157] but defects on a Q scan may be seen in CTEPH, PAH and patients with underlying parenchymal lung disease. Quantitative Q scans may reveal the presence of a right-to-left shunt.

1.7.10 Pulmonary Angiography
Pulmonary angiography was the modality of choice to map the pulmonary circulation, prior to the availability of high resolution, cross-sectional imaging modalities, which have now superseded it.  Traditional pulmonary angiography may still be performed at our institution to identify patients with CTEPH suitable for PEA in patients where other modalities are contra-indicated or have resulted in suboptimal or contradictory images.
1.8 Assessing exercise capacity
Objective assessment of exercise capacity is required at baseline and regular intervals during follow up.  This is often achieved with six minute walking test (6MWT), a submaximal exercise test where a patient walks un-encouraged as far as possible in 6 minutes.[158]  Alternatively, formal cardiopulmonary exercise testing may be used. ADDIN EN.CITE [6]  However, at the Sheffield Pulmonary Vascular Disease Unit the incremental shuttle walking test (ISWT) is used.

Although RHC is essential to formally diagnose PH, it is invasive and thus unsuitable for routine monitoring of disease progression and response to therapy. Surrogate markers for survival in patients with PH have therefore been adopted such as the distance walked at 6MWT but the predictive ability of these markers has been questioned particularly due to ceiling effect. ADDIN EN.CITE [159-162]
1.8.1 World Health Organisation functional class
Patients are graded based on the degree of their functional disturbance according to the WHO functional classification, which was adapted from the New York Heart Association functional classification.[5]  Risk of death increases with worsening WHO functional class. ADDIN EN.CITE [91, 163]

Table 2 WHO functional classification in pulmonary hypertension

Class I	Patients with pulmonary hypertension but without resulting limitation of physical activity.  Ordinary physical activity does not cause undue dyspnoea or fatigue, chest pain or near syncope.
Class II	Patients with pulmonary hypertension resulting in slight limitation of physical activity.  They are comfortable at rest.  Ordinary physical activity causes undue dyspnoea or fatigue, chest pain or near syncope. 
Class III	Patients with pulmonary hypertension resulting in marked limitation of physical activity.  They are comfortable at rest.  Less than ordinary physical activity causes undue dyspnoea or fatigue, chest pain or near syncope
Class IV	Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms.  These patients manifest signs of right heart failure.  Dyspnoea and/or fatigue may even be present at rest.  Discomfort is increased by any physical activity.
1.8.2 Incremental Shuttle Walking Test
ISWT is a safe and reproducible maximal exercise test where the subject is externally paced by a progressively quickening signal on a 10m course.  ISWT has been widely studied in both COPD and heart failure. ADDIN EN.CITE [164, 165]  There is evidence from patients with heart failure that ISWT correlates more closely with peak oxygen consumption than the 6MWT[165] and further study of its potential as an endpoint in patients with PAH is warranted.[160]
1.9 Management of patients with pulmonary hypertension 
The emergence of targeted drug therapies from the late 1990‘s for patients with PAH and PEA as a definitive treatment for CTEPH revolutionised the previously limited options for these patients. ADDIN EN.CITE [69, 166]  The recognition that these forms of PH amenable to drug therapy and surgery were rare, the interventions expensive and in the case of CTEPH, associated with a high mortality in inexperienced hands, resulted in 2001 in the designation of specialist centres in the United Kingdom which adhere to national standards of care. ADDIN EN.CITE [32, 167] 
1.9.1 Supportive therapy	
Supportive therapy in PH includes aggressive treatment of right heart failure with diuretics, consideration of supplemental oxygen, anticoagulation where not contraindicated and antiarrhythmic drugs where required.[32]  Underlying medical conditions should be treated optimally and in some cases therapy for underlying conditions, may contribute to the management of PH. ADDIN EN.CITE [43, 168]  Women of child-bearing age should be counselled against pregnancy in view of the associated high risk of mortality in PH and adequate contraception is crucial. ADDIN EN.CITE [169]  As with many chronic life-threatening conditions, patients require holistic care with symptom palliation and psychological support.[170]
1.9.2 Medical management for groups 1 and 4
The therapies discussed in this section pertain to patients with PAH and to patients with CTEPH who either are not candidates for PEA, require medical therapy prior to PEA to improve haemodynamics (bridging therapy) or who continue to have symptomatic PH following PEA. 
1.9.2.1 Anticoagulation
In early studies in patients with IPAH histology specimens showed in-situ thrombosis and a survival benefit with anticoagulation was demonstrated. ADDIN EN.CITE [171, 172]  Therefore, despite the lack of prospective RCT evidence, anticoagulation is recommended in IPAH.  At the time of this study, our practice was to extend this recommendation to patients with PAH where there was no contraindication​[7]​. ADDIN EN.CITE [80] However, in porto-pulmonary hypertension anticoagulation should be avoided due to the risk of variceal bleeding. Furthermore in PAH-SSc, many patients will not tolerate long-term anticoagulation due to gastrointestinal tract vascular ectasia.  Patients with CTEPH also all require long term anticoagulation. ADDIN EN.CITE [6]
1.9.2.2 Calcium Channel blockers
An acute vasodilator response to nitric oxide or intravenous prostanoid at RHC, identifies the minority of patients with IPAH who may benefit from treatment with CCBs, approximately half of whom will achieve long term clinical stability on CCBs alone. ADDIN EN.CITE [80, 146]  Titration to high doses of CCBs is usually required and choice of agent is based on the patient’s heart rate at baseline with relative tachycardia favouring diltiazem and relative bradycardia favouring nifedipine.[174]  In patients without adequate response to CCB alone (stability in WHO functional class I or II), escalation to other pulmonary vascular therapy is recommended. ADDIN EN.CITE [6] 
1.9.2.3 Targeted pulmonary vascular therapy 
1.9.2.3.1 Disease specific therapy and clinical trials
While there is no cure for PAH, the previously progressive pulmonary vascular obliteration may be slowed or even partly reversed with modern therapies.  Disease-specific therapies have been shown to improve quality of life, increase exercise capacity and reduce the risk of hospitalisation and of mortality in the short-term. ADDIN EN.CITE [80, 175]  Although, it should be noted that there have been no long term randomised treatment trials with any therapy and long term survival benefit with currently available therapies remains unproven.[176]   Furthermore, neither a persistent reversal of pulmonary vascular remodelling nor restoration of normal pulmonary haemodynamics can be accomplished in patients with PAH using currently available therapies. ADDIN EN.CITE [177]  

Interestingly, a meta-analysis of clinical trials showed similar demographics to registry data and similar outcomes although patients enrolled in clinical drug trials are often said to be carefully selected, more stable and less severely ill than patients outside clinical trials. ADDIN EN.CITE [178, 179]
1.9.2.3.2 Pharmacological targets in PAH
The sites of action of pulmonary vascular therapy available during the time period of this study are detailed in figure 4.  In PAH, synthesis of endothelial nitric oxide and prostacyclins are diminished due to reduced expression of nitric-oxide synthase ADDIN EN.CITE [180, 181] and prostacyclin synthase ADDIN EN.CITE [182] while endothelin is overexpressed.[183]  Thus there is an imbalance with overproduction of vasoconstrictor and underproduction of vasodilator substances.  Endothelin is also mitogenic explaining in part the smooth muscle proliferation and disordered angiogenesis seen histologically. ADDIN EN.CITE [184, 185]  The defects described above are targeted by the 3 classes of approved pulmonary vascular therapies available namely, Prostaglandins, Phosphodiesterase-5-inhibitors (PDE-5-I) and Endothelin-1 receptor antagonists (ERA)​[8]​.  


Figure 4 Therapeutic pathways in PAH  


Figure 4 illustrates pathways in the pathogenesis of PAH and the sites of action of available therapies.  The pathophysiological pathways illustrated can be targeted using endothelin-receptor antagonists, nitric oxide, phosphodiesterase type-5 inhibitors, and prostacyclin derivatives. A transverse section of a small pulmonary artery from a patient with severe pulmonary arterial hypertension shows intimal proliferation and marked medial hypertrophy. Dysfunctional pulmonary-artery endothelial cells (blue) exhibit decreased production of prostacyclin and endogenous nitric oxide, with an increased production of endothelin-1, which promotes vasoconstriction and proliferation of smooth-muscle cells in the pulmonary arteries (red). Plus signs denote an increase in the intracellular concentration; minus signs denote a blockade of a receptor, inhibition of an enzyme, or a decrease in the intracellular concentration ADDIN EN.CITE [80].

Reproduced, with permission, from Humbert et al. Copyright © 2004 Massachusetts Medical Society. cAMP; cyclic adenosine monophosphate, cGMP; cyclic guanosine monophosphate.
1.9.2.3.3 Prostanoids	
Prostanoids are analogues of prostacyclin and may be administered by continuous intravenous infusion, continuous subcutaneous infusion or inhaled as an aerosol via a nebuliser.  These drugs are vasodilators through inhibition of smooth muscle cell contraction but also have effects through inhibiting platelet aggregation, decreasing inflammation, reducing proliferation and possibly through a positive inotropic effect on the right ventricle. ADDIN EN.CITE [186-192] 

The first RCT of drug therapy in PAH occurred in 1996 and established the benefit of prostacyclin analogs in severe IPAH. ADDIN EN.CITE [193]  This class of drugs has shown benefit in IPAH, other forms of PAH and in CTEPH. ADDIN EN.CITE [163, 193-200]  For patients in WHO functional class IV, intravenous prostanoids are the recommended therapy where appropriate due to the survival benefits. ADDIN EN.CITE [6]
1.9.2.3.4 Endothelin-1 receptor antagonists
Endothelin activation plays a prominent role in the pathogenesis of PAH.  At the time of this study, available orally-active ERAs included Bosentan® and Ambrisentan®.  Sitaxentan® was also available in the United Kingdom from 2006 until 2010 when it was withdrawn following cases of fatal hepatic failure. ADDIN EN.CITE [201]  

RCTs have demonstrated the efficacy of ERAs in IPAH, PAH-CTD, PAH-CHD-Eisenmenger’s and CTEPH. ADDIN EN.CITE [202-210]  
1.9.2.3.5 Phosphodiesterase-5-inhibitors
PDE-5-Is such as Sildenafil result in pulmonary vasodilation through blocking the degradation of cytoplasmic cyclic guanosine monophosphate, increasing the vasodilatory activity of endogenous nitric oxide. ADDIN EN.CITE [211]  As with the other classes of pulmonary vascular therapies, PDE-5-Is also have antiproliferative actions in the pulmonary artery. ADDIN EN.CITE [212]

There is evidence of clinical improvement in patients with IPAH, PAH-CTD, PAH-CHD and CTEPH when treated with oral PDE-5-Is. ADDIN EN.CITE [211, 213- ADDIN EN.CITE 217]
1.9.2.3.6 Selection of therapy
Choice of treatment depends on clinical context, disease severity, patient preference and the availability of funding. ADDIN EN.CITE [32, 167, 175]   In the United Kingdom at the time of this study, patients in WHO functional class 3 and 4 were eligible for treatment and those with milder disease received treatment only in exceptional circumstances, despite growing evidence of the benefit of early therapy. ADDIN EN.CITE [218]  Patients on therapy need regular reassessment and those who demonstrate an inadequate clinical response or deteriorate following an initial favourable response with monotherapy, require escalation of their therapy to combination therapy, where two or more drugs from different classes are used in combination.  While the approach of combining different agents to augment the clinical response has a strong rationale and is widely adopted, the literature regarding long term outcomes for patients treated with combination therapy is sparse with no head-to-head comparisons and questions remain regarding the choice of combination agents and optimal timing.[32]  Treatment strategies therefore rely on experienced physicians evaluating the effect of therapy in individual patients to achieve the best possible outcome.  The synergistic effect of combination treatment influencing multiple pathogenic targets simultaneously may improve clinical status.[219]  In addition, the importance of early therapy ADDIN EN.CITE [218] and goal-orientated therapy is increasingly recognised.[220]
1.9.2.4 Medical management of groups 2, 3 and 5
For PH-LHD, there is no specific therapy for PH and management is aimed at optimising the treatment of the underlying disease.  RCTs of both prostanoid and ERA therapy in PH-LHD were terminated early due to increased mortality in the drug-treated arm. ADDIN EN.CITE [221-223]  A further study found improvements in exercise capacity and quality of life in patients with PH-LHD treated with Sildenafil compared to placebo but this was a small study with only 34 patients over 12 weeks. ADDIN EN.CITE [224]  Moreover, the RELAX trial found no benefit in any clinical endpoint for 113 patients using sildenafil for 6 months compared to those in the placebo arm, although PH was not required for entry into this study. ADDIN EN.CITE [225]  In addition, there was a trend towards more adverse events in the patients taking sildenafil.  Further long term studies are needed employing robust endpoints such as survival and focusing on patients with PH out of proportion to left heart disease who are likely to find the greatest benefit from pulmonary vasodilators.  Currently targeted pulmonary vascular therapy cannot be recommended for patients in group 2.

Treatment for patients with PH-lung is further discussed in Chapter 2.  Some subgroups of group 5 are eligible for the same targeted pulmonary vascular therapies as patients with PAH.   For example, small studies of patients with PH-sarcoidosis describe favourable response to pulmonary vasodilator therapy. ADDIN EN.CITE [226] 
1.9.3 Surgical Management
1.9.3.1 Pulmonary Endarterectomy Surgery
PEA is usually performed through a median sternotomy incision and requires the patient to be placed on cardiopulmonary bypass and undergo periods of total circulatory arrest under deep hypothermia to allow the chronic thromboembolic material to be dissected from the main, segmental and sub-segmental pulmonary arteries in a bloodless field.[227]  Surgical disobliteration of the pulmonary arteries by PEA is recommended for patients with CTEPH with surgically accessible disease. ADDIN EN.CITE [228]  The goal of PEA is to improve haemodynamics, survival and quality of life.  Haemodynamic response to PEA may be dramatic and sustained and PEA may be curative in appropriately selected patients but long term outcomes in patients who survive the perioperative period are good regardless of whether PH persists postoperatively or not. ADDIN EN.CITE [69]
1.9.3.2 Transplantation 
Suitable patients with features suggestive of a poor prognosis who fail to respond to targeted therapies adequately should be referred for consideration of transplantation in a timely manner.  Most patients with PH undergoing transplantation receive bilateral lung transplants ADDIN EN.CITE [229] although in some situations such as CHD, bilateral lung and heart transplant may be required.[230]
1.9.3.3 Atrial Septostomy 
Patients with severe right heart failure and/or significant syncopal symptoms resistant to medical therapy may rarely undergo atrial septostomy.  This procedure creates a right-to-left shunt with the aim of increasing systemic cardiac output by decompressing the right heart. ADDIN EN.CITE [231, 232]  The rationale behind this procedure was the improved survival observed in patients with PAH in the presence of a patent foramen ovale[233] and atrial septostomy has been employed as a bridge to transplant. ADDIN EN.CITE [234] 
1.10 Patient Registries
1.10.1 Definition of a Registry
A patient registry is an organised system that uses observational study methods to collect uniform data to evaluate specified outcomes for a population defined by a particular disease or exposure that serves one or more predefined scientific, clinical or policy purposes.[235] 
1.10.2 Previous registries in pulmonary hypertension
In the early 1980s, the National Heart, Lung and Blood institute of the National Institutes for Health (NIH) created the first multicentre registry of patients with IPAH to characterise long term outcomes. ADDIN EN.CITE [91]  This study was performed in an era prior to the availability of disease-specific therapy and thus describes the natural history of IPAH with supportive treatment alone.  Median survival was extremely poor at 2.8 years and the NIH prediction of survival probability equation was derived to assist with prognostication (figure 5).  This equation has also been widely used as a comparator when assessing the impact of therapies on mortality. ADDIN EN.CITE [236] 

Figure 5 NIH survival prediction equation  ADDIN EN.CITE [91]

                Probability of patient survival at time t = [H(t)] A (x,y,z)Where	 	H(t)= [0.88-0.14t+0.01t2]                      t=time interval in years from diagnosis	                      A(x,y,z)=e (0.007325x + 0.0526y – 0.3275z)                      x=mPAP                      y=mRAP                      z=CI

In the modern era this equation has consistently underestimated actual survival. ADDIN EN.CITE [237]  More recently the USA PH Connection registry has updated the equation to better reflect contemporary survival but keeping the same 3 haemodynamic variables.[54]

The majority of studies in PH since the NIH registry have focused on group 1 (PAH), individual subtypes of group 1 and group 4 (CTEPH) and include national registries from France and the United Kingdom and the REVEAL registry, a large, prospective, multicentre, observational registry designed to characterise the contemporary PAH population in the USA. ADDIN EN.CITE [11, 29, 55, 69, 237]  These studies have shown that over the past 3 decades, in addition to the advent of targeted pulmonary vascular therapies, the characteristics of patients diagnosed with PAH have changed. ADDIN EN.CITE [29, 69, 91, 113, 238-243]  Patients are older at diagnosis and have more co-morbid disease.  ADDIN EN.CITE [11, 54, 244]
 
Other registries were set up with a specific purpose such as the Surveillance of North American Pulmonary Hypertension (SNAP) registry and Surveillance of PH in America (SOPHIA) registry with the aim of determining whether anorexigen use in the USA was associated with an increased incidence of PH. ADDIN EN.CITE [19, 21] 






Table 3 Catheter-based registries in PH providing information on incidence, survival and predictors of survival

Registry	Years recruited	Diagnostic groups	Number of cases	Incident cases	Incidencecases/year per million	Survival 1yr	Survival 3yr	Predictors of survival
Patient registry for characterisation of PPH ADDIN EN.CITE [91]USA32 centres	1981-1986	IPAH	194	All	NA	IPAH 68%	IPAH 48%	RAP, mPAP, CI,  WHO functional class, Raynaud’s phenomenon
Chinese PAH ADDIN EN.CITE [245]2 centres​[9]​	1999-2004	IPAH	72 (32 with RHC)	All	NA	IPAH 68%	IPAH 39%	NA
Scottish Registry[246]Single centre	1986-2006	PAH	374	NA	PAH 7.6	NA	NA	NA
PPH in Israel[247]10 centres	1988-1997	IPAH	44	All	IPAH 1.4	IPAH 82%	IPAH 57%	MPAP, RAP ,CI
PH connection [54]Single centre	1982-2006	PAH	578(521 with RHC)	82 	NA	PAH 86%Incident 85%	PAH 69%	RAP, CI, age, WHO functional class
UK national IPAH ADDIN EN.CITE [237]7 centres	2001-2009	IPAH	482 	All	IPAH 1.1	IPAH 93%	IPAH 73%	NA

Registry	Years recruited	Diagnostic groups	Number of cases	Incident cases	Incidencecases/year per million	Survival 1yr	Survival 3yr	Predictors of survival
UK national CTEPH ADDIN EN.CITE [69]7 centres	2001-2006	CTEPH	469 	All	CTEPH 1.02	Nonsurgical 82%, Surgical 88%	Nonsurgical 70%, Surgical 76%	NA
UK national CTD ADDIN EN.CITE [29] ADDIN EN.CITE 7 centres	2001-2006	PAH-CTDPH-CTD-Lung	429	All	PAH-CTD 1.55	PAH-SSc 78%PAH-SLE 78%	PAH-SSc 47%PH-lung-SSc 28%PAH-SLE 74%	WHO functional class, age, Svo2 sex
French National PAH ADDIN EN.CITE [11] ADDIN EN.CITE 17 centres	2002-2003	PAH	674 	121 	PAH 2.4	IPAH 89%	NA	NA
REVEAL  ADDIN EN.CITE [55, 113, 237, 244, 248]54 centres USA 	2006-2007	PAH	2,9671251 IPAH641 PAH-CTD	14% 	IPAH 1.1PAH 2.3	PAH 91%PAH-SSC  82%PAH-SLE 94%		WHO functional class, 6MWT, RAP, PVR, age, sex, TLco, clinical worsening subgroup of PAH​[10]​
PAH; pulmonary arterial hypertension, IPAH; idiopathic PAH includes familial and drug induced, PAH-SSc; PAH associated with systemic sclerosis, PAH-SLE; PAH associated with systemic lupus erythematosis, CTEPH; chronic thromboembolic PH, RAP; right atrial pressure, mPAP; mean pulmonary artery pressure, CI; cardiac index, WHO, world health organization, SvO2; mixed venous oxygen saturation, 6MWT; six minute walk test distance, PVR; pulmonary vascular resistance,  TLCO; gas transfer, NA; not applicable

1.10.3 The Pros and Cons of Registries
Improvements in the understanding of PAH are in part attributable to the rich data source provided by registries, lead by the landmark NIH registry in the 1980s, which described the IPAH patient population and importantly, documented the poor survival. ADDIN EN.CITE [91]  This registry shaped subsequent clinical research and provided a benchmark against which to compare survival with modern treatments.  Subsequent registries have provided more extensive characterization of patients and updated information about survival in the modern treatment era. ADDIN EN.CITE [11, 29, 69, 113]  These registries contain phenotypic information, which is crucial when defining diagnostic groups for clinical trials and updated predictive equations for survival as the original NIH equation is no longer valid. ADDIN EN.CITE [11]  

Moreover, in uncommon diseases such as PAH, registries that are designed to involve many specialist centres, allow larger cohorts of patients to be studied than would usually be possible in a single centre registry. However, one consequence particularly of multicentre registries, is the inherent rise in missing data as evidenced by the 57% completeness of TLco in the REVEAL registry for example. ADDIN EN.CITE [113]  In addition, previous studies have demonstrated that cases managed by various centres can have significantly different characteristics. ADDIN EN.CITE [11]

Registries offer a “real-world” view of a diverse population rather than enrolling only carefully selected patients as in clinical drug development studies. Registries provide insights into patient populations, epidemiology and treatment patterns. Registries also offer the opportunity to assess the effect of therapies on patients who would not have met clinical trial criteria and particularly compare therapies and combination therapies in a disease where there is a paucity of “head-to-head” comparative trials.[249]

By the nature of its derivation, registry data applies to the cohort from which it is drawn.  Comparing and contrasting patient characteristic between registries and external validation of predictive equations is important to confirm generalisability. 

Observational studies through registries may be hypothesis generating, allow initial evaluation of a hypothesis and may assist in the formulation of specific questions more amenable to prospective randomised studies.
1.10.4 Incident versus prevalent cases
Prevalent cases are patients who have been diagnosed prior to enrolment into a registry.  Incident cases are enrolled into a registry at the time of initial diagnosis.

The inclusion of both prevalent and incident patients in registries allows a greater sample size but this is at the expense of uniformity with regards to disease duration.  Patients who are prevalent at enrolment into a registry are likely to have different characteristics and outcomes to newly diagnosed patients and the need for registry data to be based on incident cases has been highlighted. ADDIN EN.CITE [250, 251]  Prevalent cases represent survivors and introduce survivor bias.  Conversely, registries that derive predictive equations based on prevalent and incident cases enable assessment of survival risk from any point in the disease course which arguably may be more useful in routine clinical practice.  In addition, due to delayed diagnosis which remains a challenge in PAH ADDIN EN.CITE [55, 252], some argue that the true natural history of the disease cannot even be assessed in an incident cohort as the time from symptom onset to diagnosis is unaccounted for. ADDIN EN.CITE [31]  
1.10.5 Rationale for the ASPIRE registry
In summary, PH is a significant condition that impacts on survival.  While modern therapies have improved the outlook for patients, more effective therapy is needed. The rationale behind the ASPIRE registry was that there was no registry data comparing the diagnostic groups across the clinical spectrum of PH in a single centre, using incident, treatment-naïve cases diagnosed by a catheter based approach.   Detailed phenotypic and outcome data are required to allow selection of patients for future RCTs and ultimately the development of more effective therapeutic strategies.
1.11 Objectives and Hypotheses
The aims and hypotheses the ASPIRE registry was designed to assess are detailed below.
1.11.1 Objectives
	To define the characteristics, outcomes and prognostic markers across all 5 diagnostic subgroups of PH.
	To compare other diagnostic subgroups to IPAH as a “gold standard” pulmonary vasculopathy.
	To assess if PH diagnostic group influences survival.
	To review if demographics and outcomes of patients seen in the current era at our centre are similar to those seen in registries from previous eras and other centres.
1.11.2 Hypotheses
	Survival will differ significantly between diagnostic groups.
	Baseline demographic and haemodynamic characteristics will differ significantly between and within the 5 groups of the diagnostic classification.
	Survival in the modern treatment era will have improved compared to historic series.
	Survival will differ significantly between subgroups within diagnostic groups.
	Survival in CTEPH will be superior in patients undergoing PEA surgery.
	The reason patients do not proceed to PEA surgery will influence outcome.
















Pulmonary hypertension in lung disease
Chapter 2: Pulmonary hypertension in lung disease
2 Pulmonary hypertension in patients with disorders of the respiratory system and/or hypoxemia

Group 3 of the WHO Updated Clinical Classification of Pulmonary Hypertension (Dana point 2008) (Figure 1) ADDIN EN.CITE [10] ADDIN EN.CITE  includes patients with PH in association with lung disease and hypoxia. Chronic respiratory diseases, such as COPD, have a high and increasing worldwide prevalence. ADDIN EN.CITE [253-255]  The development of elevated PAP in COPD is known to increase both morbidity ADDIN EN.CITE [256] and mortality. ADDIN EN.CITE [99, 257]  Thus PH in association with lung disease such as COPD potentially causes a greater clinical burden of disease than the rarer but much more thoroughly studied idiopathic form, IPAH.  In the USA, among patients admitted to hospital with respiratory disorders, it has been estimated that 28% have PH.[258]  
 
There are many unanswered questions regarding how PH in lung disease is best defined and assessed and whether treatment modalities that are successful in other forms of pulmonary hypertension can be employed.
2.1 Elevated PAP in lung disease

A diverse range of respiratory conditions may be associated with an elevation in PAP, from COPD and Idiopathic Pulmonary Fibrosis (IPF) to sleep disordered breathing and ventilatory failure related to chest wall abnormalities.  The elevation in PAP is usually mild to moderate and correlates with the degree of underlying lung disease.  In advanced respiratory disease it is common to have an elevated PAP but normal PCWP and CO implying precapillary PH.[259]  
2.1.1	Cor pulmonale
The definition of Cor pulmonale as proposed by Weitzenblum et al is “PH resulting from diseases affecting the structure and/or function of the lungs; PH results in right ventricular enlargement and may lead with time to right heart failure.”[259]

Cor pulmonale is therefore not defined by the presence of peripheral oedema.  Peripheral Oedema is common in patients with lung disease and ventilatory failure and may simply reflect neuroendocrine abnormalities inducing fluid retention​[11]​ [262] rather than being synonymous with right heart failure which tends to occur late in the disease.  ADDIN EN.CITE [263-265]  

2.1.2	Defining PH in association with lung disease; 
mean PAP >20mmHg versus >25mmHg
A PAP >20mmHg when reclining has historically been used to characterise PH in patients with lung disease, especially COPD, because a PAP above this level is always abnormal. ADDIN EN.CITE [266, 267]  However, resting PAP ≥ 25mmHg that has traditionally defined IPAH[7] has now been accepted as the universal definition of PH. ADDIN EN.CITE [91, 268]   In parenchymal lung diseases, elevated PAP on exercise predates PH at rest and is postulated to be a consequence of failure to reduce PVR by pulmonary vasodilation on exercise. ADDIN EN.CITE [269]  
2.1.3	Defining pulmonary hypertension out of proportion to lung disease

In clinical practice, patients with elevated PAP in association with underlying lung disease appear to be a heterogeneous group.  Most have mild to moderate PH with mean PAP ranging from 20-35mmHg and considered to be in proportion with the severity of their lung disease and hypoxaemia.[99] ADDIN EN.CITE [270] However, there are a minority of patients who have haemodynamics at RHC more akin to those seen in IPAH, in the setting of only moderate abnormalities on lung function and in whom pulmonary vascular disease is predominant and severe. It is this group, which has recently been individualised as PH disproportionate to the degree of lung disease ADDIN EN.CITE [270, 271] that represents a clinical challenge.

The evidence relating to PH out of proportion to lung disease is mainly described in the literature in relation to COPD but consensus of opinion is that the definition should be applied to all forms of lung disease associated PH​[12]​. ADDIN EN.CITE [259, 273]


2.2	Subcategories of lung disease associated with PH
2.2.1	PH in COPD





At the time of this study, COPD is defined by pulmonary function tests showing airway obstruction that is not fully reversible with a FEV1/FVC ratio of ≤ 0.7, in the context of a history of cough, sputum production or dyspnoea and/or history of exposure to risk factors such as cigarette smoking.[253]   

Emphysema is defined pathologically as a condition of the lung characterised by abnormal, permanent enlargement of the air spaces distal to the terminal bronchioles, accompanied by destruction of their walls.[274] However, emphysema is universally included under the umbrella of COPD.[275]
2.2.1.2 Epidemiology 
It is estimated by the WHO that COPD affects 210 million people and is the third leading cause of death worldwide. ADDIN EN.CITE [276, 277]   In the United Kingdom, the main cause of COPD is tobacco smoking, but other factors such as occupational exposure, urban living, smoking illicit substances, alpha-1 antitrypsin deficiency and childhood respiratory infections also play a role.[278]   

In the 1980s, Williams et al estimated that 60,000 people in England and Wales with COPD were eligible for long term oxygen therapy and hence at risk of PH.[279]  This illustrates the prevalence of mild to moderate PH in COPD and in order to adapt these figures for today, taking into consideration the marked increase in COPD prevalence, some authors have suggested this figure would have to be doubled.[259]  Table 4 summarises the literature with regards to prevalence of PH in COPD.
 
Historically COPD was much more prevalent in males.  However, IPAH shows strong female predominance. ADDIN EN.CITE [11, 246, 280] The proportion of COPD cases in women is rising with the equivalence of smoking habits and recognition that women are disproportionately susceptible to environmental risk factors. ADDIN EN.CITE [281, 282]   The effect this will have on the overall prevalence of severe PH in COPD is unknown.  Referral bias may also influence the identification of severe PH-COPD with women more likely to be referred to PH specialist centres for further investigation due to higher preponderance of PAH In females. 


Table 4 Prevalence of PH in COPD

Author	Study Setting	n	Severity of COPD	MeanPAP(mmHg)	Prevalence PH
Burrows[283]		50	FEV1/FVC 37 %	26	
Weitzenblum[99]	University HospitalRHC	175	FEV1/FVC 40.2 %		35.4 %mPAP >20 mmHg
Weitzenblum[284]	University HospitalRHC	93			34.3%
Oswald- Mammosser[285]	University HospitalRHC	151	Mean FEV1/FVC 38%		20.5%mPAP >20mmHg
Vizza[286]	Lung transplant assessmentRHC	168	Mean FEV1 20%	25	RV dysfunction 59%
Scharf[287]	LVRS TrialRHC	120	Mean FEV1 27%	26	90.8 %mPAP >20 mmHg
Arcasoy ADDIN EN.CITE [288]	Lung Transplant assessmentRHC	253			18%sPAP ≥45mmHg
Thabut ADDIN EN.CITE [271]	LVRS & Lung Transplant assessmentRHC	215	Mean FEV1 23.9%	26.9	50.2 %mPAP >25 mmHg
Blundin[289]	CommunityECHO only	212	Mean FEV1 55.7%	(sPAP 48)	35.4%sPAP ≥35mmHg
n=number of patients; LVRS = lung volume reduction surgery
Table 4 summarises the evidence published to date on the prevalence of PH in COPD.  One major limitation is that patients referred to centres for assessment for lung transplant and LVRS cannot be considered representative of all patients with COPD.  This group has advanced disease and selection bias is against comorbidities such as significant left heart disease.  A further limitation of many of these studies is the variable gender distribution. Proportion female in these studies ranges from 1.1% [99]to 61.9%[286].  
2.2.1.3 Characteristics of patients with severe PH associated with COPD

The impact of PH on survival in COPD is well known.  In one study, 5 year survival was <10% in patients with mPAP >45mmHg compared to a 5 year survival of >90% among patients with COPD and mPAP <25mmHg.[290]

In 2000, Stevens et al reported 5 patients (3:2 ♂:♀) from a cohort of 600 patients at a PH tertiary referral centre with COPD and severe PH (mPAP >40mmHg).[291]  In the NETT study, involving patients with severe emphysema assessed for lung volume reduction surgery (LVRS), 5% had a mPAP >35mmHg.[287]  These studies provoked interest in characterising further the minority with COPD and severe PH resulting in 2 landmark papers.

Cluster analysis of 215 patients with severe COPD assessed for lung transplant and LVRS demonstrated a small group of patients with high PAP but only mild to moderate airflow obstruction. ADDIN EN.CITE [271]  These patients were more hypoxemia and less hypercapnic than the other COPD patients in this series.

Similarly, Chaouat et al retrospectively reviewed 998 patients with COPD under going RHC for evaluation of chronic respiratory failure. ADDIN EN.CITE [270]  Eleven patients (1%) had severe PH with mPAP ≥ 40mmHG and no other discernable cause for their PH.  All 11 patients were men and current or ex-smokers.  Also, all 11 were more hypoxaemic and less hypercapnic than matched controls.  Pulmonary function showed moderate airflow obstruction with median FEV1 50% predicted and FEV1:FVC ratio 49%.  TLco was much reduced in those with severe PH and correlated with emphysema score on CT scan.  It is noteworthy that when extrapolated the prevalence of severe PH in COPD in this French study is similar to the prevalence of IPAH in France. ADDIN EN.CITE [11, 292]

Conversely, in the USA, 2 groups demonstrated that in COPD worsening PH was associated with worsening airflow obstruction measured by FEV1 suggesting the two processes progress simultaneously and not in keeping with the cluster of patients described above ADDIN EN.CITE [285, 287, 293]. 
2.2.1.4 Clinical impact and prognosis
In COPD, patients with PH have more impaired exercise capacity than their counterparts with normal PAP through increased ventilation perfusion mismatch on exercise. ADDIN EN.CITE [281, 294-296]  Also, in COPD, patients with mPAP >18mmHg are at increased risk of an exacerbation requiring hospitalization. ADDIN EN.CITE [256]  

PH in COPD is associated with reduced survival inversely proportional to the level of PAP. ADDIN EN.CITE [99, 256, 267, 297]  Five-year survival has been quoted as 33% in COPD with PH compared to 66% without PH.[298]
2.2.2	PH in Interstitial Lung Disease
Interstitial lung disease (ILD) is a heterogeneous group of diffuse parenchymal lung diseases with histology differing between entities.  This group does not include patients with lung disease in the context of connective tissue diseases such as systemic sclerosis.  Most of the literature regarding PH in ILD focuses on IPF which is the most common idiopathic interstitial pneumonia.    

Of note, PH associated with some conditions that affect the lung interstitium such as sarcoidosis, fall under group 5 in the 2008 Classification of PH (Figure 1) due to multi-factorial underlying mechanisms and a less clear link to hypoxaemia (discussed further in section 1.4.5).
2.2.2.1 Definitions
IPF is a disease of unknown aetiology typified by progressive parenchymal fibrosis.  IPF can be diagnosed following internationally agreed criteria, in the absence of other known causes of ILD when pulmonary function tests, radiology and, if available,[299] histology are supportive of the diagnosis. ADDIN EN.CITE [300, 301] 
2.2.2.2 Epidemiology
IPF has an incidence of 3-42/100,000/year in the developed world ADDIN EN.CITE [302-305] but in the more elderly this figure rises to 200/100,000.[304] United Kingdom figures suggest the incidence to be >4000 new cases per annum[303] and median survival from diagnosis is 2-3years. ADDIN EN.CITE [306-308]

Early studies, using ECHO estimates of sPAP, suggested PH in IPF was common with prevalence between 36% and 84%. ADDIN EN.CITE [309, 310] ADDIN EN.CITE 

The USA lung transplant registry has revealed a prevalence of PH in IPF of 46.1% defined by a mean PAP ≥ 25mmHg at RHC.  Furthermore, 9.1% had PH classified as severe with a mPAP ≥ 40mmHg.[311]  Single centre experience in lung transplant candidates corroborates these findings with a prevalence of PH in ILD 20-31.6% at RHC. ADDIN EN.CITE [312, 313]  The main limitation in these retrospective cohorts is selection bias as all cases were listed for transplant, suggestive of younger patients without comorbidities but with more advanced interstitial disease.  The only published work outside lung transplant assessment that includes RHC data quoted a prevalence of PH in ILD of 8.1%. ADDIN EN.CITE [314]  This may be more representative of the wider IPF community, as severity of IPF by pulmonary function was generally milder in this study.
2.2.2.3 Characteristics of patients with PH in ILD
In the majority of studies, there were no gender predilections for PH in ILD. ADDIN EN.CITE [311, 313]  In IPF, African-Americas may be twice as likely to have severe PH compared to Caucasians even controlling for other markers of ILD severity. ADDIN EN.CITE [311, 315] 

No correlation has been shown between FVC in isolation and either the likelihood of developing PH or the severity of PH in IPF suggesting that progression of parenchymal destruction reducing lung volumes is not the mechanism driving PH. ADDIN EN.CITE [119, 309, 311, 313, 316]  Greater reduction in TLco has been associated with PH in ILD ADDIN EN.CITE [313, 314, 316] and this is borne out clinically by greater likelihood of requiring supplemental oxygen. ADDIN EN.CITE [311, 313]

A prediction equation to predict mPAP in IPF that inputs FVC%, TLco% and resting pulse oximetry on room air has been proposed and validated in small numbers but requires external validation in larger numbers and a broader spectrum of IPF severity. ADDIN EN.CITE [317, 318] 
2.2.2.4 Clinical impact and prognosis
IPF patients with PH have a greater exercise limitation than those without when matched for confounding variables. ADDIN EN.CITE [313, 319]

At Kaplan-Meier analysis, early significant differences were seen between the survival in IPF with and without PH with 1 year mortality 5.5% versus 28.8% respectively.[313]  Overall, the presence of PH in IPF increases mortality by three to six fold ADDIN EN.CITE [313, 320] and more than halves median survival. ADDIN EN.CITE [314]

It is intuitive that those with more severe PH will have a worse outcome but in contrast to COPD, there is no clearly delineated group with PH “disproportionate” to ILD.  Only one study assessed degree of PH and survival.  The median survival in severe PH (sPAP >50mmHg) was 0.7yrs compared to 4.1yrs in those with milder PH (sPAP 36-50mmHg) and 4.8yrs without PH.[309]  However, this study used ECHO measurements and due to the tendency to overestimate PAP more frequently at sPAP <45mmHg ADDIN EN.CITE [288], may have contaminated the group with mild PH with false positive diagnoses of PH. 
2.2.3	PH in pulmonary disease with a mixed restrictive and obstructive pattern
This subgroup includes cystic fibrosis ADDIN EN.CITE [321, 322] and bronchiectasis ADDIN EN.CITE [323] where the prevalence of PH is examined in small studies only.  It also includes combined pulmonary fibrosis and emphysema syndrome (CPFE).
2.2.3.1 Combined pulmonary fibrosis and emphysema      syndrome 
This coexistence of pulmonary fibrosis and emphysema, was first reported in 1990[324] but the syndrome has recently been described as a separate entity defined by CT scan findings of lower zone fibrosis with emphysema of the upper zones. ADDIN EN.CITE [325]  This syndrome is characterized by male sex and current or previous smoking. ADDIN EN.CITE [325] 

The prevalence of PH in this group is high, 48% in the only study using RHC[326] and 72% in a slightly larger cohort assessed by ECHO alone. ADDIN EN.CITE [327] The prognosis is poorer than in patients with IPF without emphysema ADDIN EN.CITE [327] and the presence of PH independently predicts very poor prognosis in the region of 25% 5 year survival. ADDIN EN.CITE [325, 327]  Lung volumes in CPFE are better preserved despite much reduced TLco and as such pulmonary function is unlikely to adequately monitor disease progression. ADDIN EN.CITE [328, 329]  CPFE has a phenotype and prognosis distinct from IPF and it has been suggested that future therapeutic trials in IPF must either take account of or exclude this group to avoid distorting results. ADDIN EN.CITE [330, 331] 

2.2.4	Sleep disordered breathing, alveolar hypoventilation disorders, chronic exposure to altitude and developmental abnormalities 

PH out of proportion to other categories of lung disease listed in the Clinical Classification of PH (Figure 1) ADDIN EN.CITE [10] has not yet been studied extensively. 

A review of 8 previous studies estimated the prevalence of mild PH in patients with OSA to be 15-20%.[114]  The degree of PH may be more severe in patients with OSA combined with obesity hypoventilation syndrome or other causes of hypoxaemia.
2.3	Identifying PH in patients with chronic respiratory conditions
Dyspnoea is a cardinal feature of both lung disease and pulmonary hypertension and studies have revealed the difficulties of attributing breathlessness to the correct cause on clinical grounds alone. ADDIN EN.CITE [332, 333] ADDIN EN.CITE   When patients with lung disease experience a clinical deterioration not matched by a decline in pulmonary function, the clinical suspicion of PH should be high and further investigation arranged. 
2.3.1	Doppler echocardiogram 
ECHO is recommended as the initial non-invasive investigation to evaluate patients for evidence of PH, however, the accuracy of ECHO in patients with respiratory disease has been questioned by more recent studies showing discordance up to 10mmHg between pressures obtained at ECHO and RHC in more than half of patients. ADDIN EN.CITE [129, 334]  This is in contrast to studies in patients with IPAH or PAH associated with other conditions such as portal hypertension and connective tissue disease where, although small patient numbers, there was good correlation between ECHO and RHC parameters. ADDIN EN.CITE [133, 194, 335, 336]

In patients with advanced lung disease being considered for lung transplant, it was only possible to estimate sPAP at ECHO in 44% and ECHO frequently overestimated sPAP. ADDIN EN.CITE [288]  Topographic factors such as hyperinflation and obesity, which are common in patients with lung disease, are cited as contributing to the inaccuracy of ECHO by altering the position of the heart in relation to the doppler probe leading to difficulties obtaining clear acoustic windows.[337]  This is borne out by the findings that in patients with obstructive lung disease there is less success estimating sPAP at ECHO compared to those with fibrotic lung disease ADDIN EN.CITE [286, 288, 338] and in subgroups of COPD with high residual lung volumes (implying significant hyperinflation), success rates in estimating sPAP are especially poor. ADDIN EN.CITE [288]  Overall, in severe COPD the frequency of successfully estimating sPAP at ECHO is 30%. ADDIN EN.CITE [288, 339, 340]  ECHO appears more accurate when sPAP is >45mmHg inflating its negative predictive value ADDIN EN.CITE [288] but if inadequate images are obtained further investigation is warranted because in up to one third of patients with IPF in whom no ECHO sPAP could be obtained, RHC confirmed PH. ADDIN EN.CITE [338] 

To further confound the estimation of PAP by ECHO in patients with lung disease, PAP is variable depending on physiological conditions and fluctuations in disease state, such as infective exacerbation, that induce hypoxic vasoconstriction (table 5).
Table 5 Causes of elevation in PAP

Situation	Rise in MPAP	References
Exacerbations	>20 mmHgCorrelates with hypoxiaReturns to baseline	Abraham et al [341]Horsfield et al [342]Weitzenblum [343]
Exercise	25-30 mmHg	Burrows et al [283]Horsfield et al [342]Fletcher et al [344]
Sleep(without coexistent sleep apnoea[345])	16-20 mmHgRise in mPAP reduced by O2	Coccagna et al [346]Raeside et al [347]Fletcher et al [348]
Time	0.3mmHg/yr-2.8 mmHg/yr	Kessler et al [293]Weitzenblum et al [284]MRC [349]

Table 5 This data is mostly derived from work in COPD and is of particular note with regard to the prevalence of PH in COPD.  Kessler et al followed 131 COPD cases over 6 years and found a slow progression in PAP over time, with PH on exercise predicting the development of PH at rest.[293] In this study, 25% developed PH suggesting a significant number of COPD patients will develop PH over the course of their disease.  

In summary, in clinical stability, an estimated sPAP of <40mmHg with no dilatation of the right heart on ECHO makes PH unlikely but if sPAP is >40mmHg corroboration with RHC should be sought as it will be a false positive finding in approximately 50%. ADDIN EN.CITE [288, 338, 340, 350]  Other parameters may also be useful.  A recent study in patients with COPD referred for lung transplantation, has suggested that pulmonary artery:aorta ratio measured on CT scan correlates better with the mPAP at RHC and is therefore of greater value in the identification of PH in severe COPD than ECHO.[351]






Figure 6 Strategy for approaching the investigation of patients with lung disease in whom PH is suspected
Adapted from Kiely, DG; Presentation British Thoracic Society Summer Conference July 2009, reproduced with permission
	Figure 6 Firstly, undiagnosed LV dysfunction, which is prevalent in many lung diseases, should be excluded. ADDIN EN.CITE   Investigations are then aimed at identifying those with elevated PAP but also assessing severity of lung disease and excluding other causes of PH that would require a different treatment strategy such as IPAH and CTEPH ADDIN EN.CITE [270] ADDIN EN.CITE .Awareness of the performance characteristics of each investigation is crucial to interpretation.  ECHO is poor at discriminating severity of PH ADDIN EN.CITE . ADDIN EN.CITE [129, 355]  In the future, increased sensitivity of ECHO and combination with other physiological and biochemical measures may allow a more accurate prediction model for the presence of PH in patients with lung disease to be developed and validated in prospective studies.     





A reliable prognostic algorithm for PH out of proportion to lung disease is urgently needed to refine the triage of patients for complex and expensive treatments including transplant.  Biomarkers may contribute to the crucial distinction between significant pulmonary vascular disease and mild secondary PH in lung disease when used in conjunction with other demographic and physiological data. ADDIN EN.CITE [319, 356] ADDIN EN.CITE   Possible candidates are discussed further in Appendix 1.  
2.4	Prognosis of PH in patients with lung disease
It is difficult to untangle the mortality associated with PH specifically from that due to respiratory failure or other complications of the underlying lung disease.  As detailed above, there have been many studies suggesting survival is poorer in those with elevated PAP compared to matched subjects without PH. 
2.4.1	RHC measures that predict outcome in PH-Lung
PAP is used to define PH but may not be the strongest haemodynamic predictor of overall survival in PH associated with lung disease.  There is some debate in this regard with work by Corte et al ADDIN EN.CITE [357] suggesting PVR to be superior to mPAP and right ventricular systolic pressure in patients with ILD in contrast to other studies. ADDIN EN.CITE [257, 309, 313, 314]  However, in COPD, PAP has been shown to have good prognostic value.[298]  Further work is required in this regard with consideration of more complex haemodynamic parameters such as degree of rise in PAP on exercise.[358]
2.4.2	PH out of proportion to lung disease in context: Registry data
The published data from national registries of PH has demonstrated an increase in the incidence of diagnosed PH over the last decades. ADDIN EN.CITE [238, 359]  This may be partly due to increased access to ECHO and increased awareness of targeted pulmonary vascular therapies shown to alter outcome.  Historically, registries have focused on group 1 PAH and none of the national registries have included patients with PH associated with lung disease to directly compare haemodynamic characteristics and survival with other groups of PH patients treated synchronously in the same centres. ADDIN EN.CITE [11, 55, 238,  ADDIN EN.CITE 245, 246] 

2.5	Pathogenesis of PH associated with lung disease and hypoxia

Historically, in PH out of proportion to lung disease, 3 factors were postulated as causative in pulmonary vascular remodelling.  Recent insights have lead to debate in the literature surrounding whether traditional hypotheses are supported and what role cigarette smoke plays. ADDIN EN.CITE [360, 361] 

Potential shared common pathogenic mechanisms have been described for fibroproliferation in ILD and in PH ADDIN EN.CITE [312, 353, 362] and the assessment of common aetiological factors such as smoking continues.  Patients with severe PH out of proportion to respiratory disease exhibit a distinct clinical pattern similar to IPAH and the underlying cellular signalling pathways are almost certainly alike but this has yet to be fully determined.  Multifactorial mechanisms are likely to be implicated in the pathogenesis of PH out of proportion to lung disease with contributory factors unique to the underlying respiratory disease.
2.5.1 Traditional hypotheses  	
2.5.1.1 Hypoxia 
Alveolar hypoxia due to structural lung disease and impaired control of breathing causes vasospasm largely in arterioles.  This vasoconstriction is an adaptive response to redirect blood flow to better ventilated parts of the lung and improve ventilation-perfusion matching and is controlled by both endothelial vasoactive mediators ADDIN EN.CITE [363, 364] and the affect of hypoxia on smooth muscle in the vessel wall. ADDIN EN.CITE [365, 366]

When occurring chronically, hypoxia leads to persistent vasospasm and triggers abnormalities in the pulmonary arterial bed including thickening of the media tunica, eccentric intimal proliferation and local thrombotic conditions. ADDIN EN.CITE [367, 368]  This vascular remodelling can continue even when hypoxaemia is corrected and inflammation is implicated by the influx of pro-inflammatory cytokines and cells seen in sustained hypoxia. ADDIN EN.CITE [369]  This is thought to be the predominant mechanism for PH in lung disease.[259]  

This raises the question of how in IPF, where resting hypoxaemia is a late feature, hypoxia could underpin the development of pulmonary vascular disease.  Nocturnal and exercise desaturation are common and under recognised in IPF ADDIN EN.CITE [370, 371] and may drive the development of PH through Endothelin 1. ADDIN EN.CITE [361, 372, 373] However, clinical studies have failed to show PaO2 is a direct predictor of PAP so hypoxia is not the whole story. ADDIN EN.CITE [287, 298]
2.5.1.2 Damage to pulmonary vasculature 
The pulmonary vascular bed can undergo fibrotic obliteration as the lung parenchyma is destroyed in both emphysema and ILD leading to increased PVR.[286]  This mechanism cannot however explain PH that is disproportionate to the underlying lung disease.
2.5.1.3 Hyperinflation 
Hyperinflation can compress alveolar vessels through mechanical stress and historically was thought to cause PH in emphysema. ADDIN EN.CITE [264, 374, 375]  The magnitude of this affect is now refuted as in patients undergoing LVRS, which should reduce gas trapping, no significant change in PAP is seen postoperatively.[360]  However, this may simply indicate that PH persists because vessel compression is fixed.
2.5.2 The effect of smoking
Cigarette smoke is known to increase muscularization of pulmonary arteries ADDIN EN.CITE [374, 376-378], reduce pulmonary artery compliance[379] and affect endothelial dysfunction through inflammatory reaction in the vessel wall[377] and up regulation of vasoactive mediators. ADDIN EN.CITE [360, 380]  These effects may persist after smoking cessation ADDIN EN.CITE [375, 381] and smoking may account for pulmonary vascular remodelling in normoxic individuals via inflammatory pathways. ADDIN EN.CITE [378, 382]
2.5.3 The right ventricle
Another important consideration is the effect the obliteration of the pulmonary vascular bed has on the right ventricle culminating in right ventricular dysfunction which ultimately determines symptoms and survival. There is a scarcity of literature on right ventricular remodelling in lung disease specifically.
2.5.4	An overlapping pathogenesis




2.6	Treatment of pulmonary hypertension associated with lung disease

Treatment in the majority of patients with respiratory disease with mild and proportional increases in their PAP is aimed at optimal treatment of the underlying condition with the addition of supportive therapies such as supplemental oxygen to correct chronic alveolar hypoxia considered an important determinant in the development and perpetuation of elevated PAP. ADDIN EN.CITE [349, 385]  Two trials have demonstrated reduced mortality from long term oxygen in patients with COPD and hypoxaemia and/or cor pulmonale. ADDIN EN.CITE [349, 385]

Patients with severe PH out of proportion to lung disease may have severe haemodynamic impairment similar to patients with IPAH and the use of therapies frequently prescribed in IPAH has been considered for this group.  However there is relatively little evidence to support this with no large, prospective RCTs with long term outcomes regarding safety and efficacy. ADDIN EN.CITE [270, 273]  It is hypothesised that the use of targeted therapy may be restricted by deleterious effects on gas exchange worsening hypoxia[361] but consensus is that treatment is likely to be appropriate for highly selected cases with severe PH, supervised by designated, tertiary referral centres.[353]

Consideration of referral for lung transplantation is important in advanced lung disease and some authors have suggested that priority should be given to those with PH in view of the associated reduction in survival and evidence of progression of PH while on transplant waiting lists. ADDIN EN.CITE [357, 386]  Patel et al found a 50% increase in risk of death in IPF awaiting transplant for every 5mmHg rise in PAP.[312]
2.7 In summary

	Studies evaluating the prevalence of PH are needed in the wider lung disease population outside transplant and LVRS candidates.
	Distinguishing proportionate and disproportionate PH is crucial in explaining the differences in pathogenesis and clinical phenotypes of these groups.
	Development of PH may explain symptomatic decline in a patient with lung disease where pulmonary function is preserved.
	One can hypothesise that patients with PH out of proportion to lung disease will benefit from targeted pulmonary vascular therapies but RCTs are required before therapy can be recommended.
2.8 Objectives and hypotheses
The ASPIRE registry offers the opportunity to further understand the natural history of PH-Lung and describe baseline phenotypes with the emphasis on the crucial distinction between proportionate and disproportionate PH in COPD.  Furthermore, phenotyping the largest cohort of patients with severe PH-COPD published to date, provides insights into the effect of targeted pulmonary vascular therapies in this group and describes predictors of survival that should be considered when designing multicentre RCTs of therapy in PH-COPD. Objectives and hypotheses are listed below.
2.8.1 Objectives
	To determine the baseline characteristics of patients with mild to moderate compared to severe PH-COPD.
	To analyse outcomes in patients with PH-COPD.
	To describe prognostic markers of patients with PH-COPD.
	To assess whether severe PH-COPD is amenable to pulmonary vascular therapy.
	To assess the safety of targeted pulmonary vascular therapy in PH-COPD with regard to degree of hypoxaemia.
	To assess whether an mPAP of 40mmHg is the optimal level to define those patients with poorer outcome.
2.8.2 Hypotheses
	The characteristics of patients with mild to moderate PH-COPD will differ from those of patients with severe PH-COPD.
	The outcome of patients with severe PH-COPD will be inferior to that of mild to moderate PH-COPD.




















The methods used throughout this thesis are described in this chapter.
3.1 The Sheffield Pulmonary Vascular Disease Unit 
The Sheffield Pulmonary Vascular Disease Unit is the largest of 7 adult PH centres in the United Kingdom[387], serving a referral population of approximately 15 million and assessing and managing patients across the entire clinical spectrum of PH. Our quaternary referral service has adopted a systematic approach to the evaluation of all patients with suspected PH including multiple imaging modalities, exercise testing and RHC with diagnosis made following multidisciplinary review of each case.  This provides an opportunity to compare characteristics, treatments and outcomes within and between the different forms of PH in a group of unselected, consecutive, extensively phenotyped, treatment-naïve patients in the era of the advent of targeted drug therapies. 
3.1.2 Referrals 
Patient referrals are accepted from a wide geographical area and from doctors in secondary care working in any specialty.  Patients were referred for specialist assessment due to symptoms, signs or imaging features suggestive of PH. 
3.1.2.1 Screening for PAH
In 2002, the Sheffield Pulmonary Vascular Disease Unit screening protocol for PAH-CTD (figure 2) was introduced advocating annual ECHO and TLco in SSc / MCTD and baseline ECHO and TLco in SLE. Specialist referral is advised if TG is >40mmHg or TG 30-40mmHg with TLco<50% or unexplained breathlessness.  Over subsequent years, this protocol was progressively disseminated amongst Rheumatology centres referring to our unit.  

In addition patients undergoing assessment for liver transplantation, are also commonly screened for portal PAH as recommended in liver transplantation guidelines.[48]
3.2 ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a REferral centre) registry

The details of all patients diagnosed with pulmonary hypertension at the Sheffield Pulmonary Vascular Disease Unit were recorded prospectively on departmental databases.  A single investigator (JH) performed a review of hospital records for all adult (≥ 16 years), incident cases of PH to confirm the recorded diagnosis and collect clinical data.  Results of pulmonary function tests and WHO functional class obtained closest to date of RHC were recorded.  Date of diagnosis was taken as date of first RHC showing PH, except in patients with Eisenmenger’s syndrome in whom RHC is not routinely required[209], where date of diagnosis was taken as date first seen at our centre. 

All patients underwent a standard, systematic diagnostic evaluation including ECHO, detailed blood testing, exercise testing, lung function testing, overnight oximetry, isotope perfusion scanning, HRCT, CTPA and RHC. Cardiopulmonary MRI was routinely performed from 2004 while formal pulmonary angiography was performed when indicated.  Diagnostic classification was by standard criteria following multidisciplinary assessment by experienced pulmonary vascular physicians and specialist radiologists.  

Patients were assigned primary, secondary and tertiary pulmonary vascular diagnoses as applicable and for the purposes of analysis, primary pulmonary vascular diagnosis was used.  Systematic and thorough screening of each case was undertaken by the single investigator (JH) using strict predetermined clinical and haemodynamic criteria to verify each diagnosis and update diagnoses using the latest diagnostic categories where necessary. ADDIN EN.CITE [6]  Every effort was made to include only patients who fulfilled current criteria for their diagnostic group and subgroup.


Figure 7 Diagnostic process
*cardiopulmonary MRI was used routinely from 2004 onwards.  
Abbreviations ECG, electrocardiogram, ECHO, Echocardiography, PFTs, pulmonary function testing; ISWT, incremental shuttle walking test; CXR, chest X-ray; CTPA, CT pulmonary angiogram; HRCT, high resolution CT thorax; MRI, magnetic resonance imaging; USS, ultrasound scan; TOE, transoesophageal ECHO; 

3.2.1 Case definitions and exclusion criteria
3.2.1.1General Exclusions
Patients who did not undergo RHC at baseline were excluded from the cohort.
Patients with PH on exercise (defined as a mPAP ≥ 30mmHg on exercise) but not at rest were excluded unless they later developed PH at rest in which case the date of diagnosis of PH at rest at repeat RHC was taken as their date of onset of the disease. Patients were excluded if PH was attributable to multiple factors in unrelated diagnostic groups.  Patients who did not meet the inclusion criteria for their diagnostic subgroup were excluded rather than reclassified.

Rarely patients were commenced targeted therapy on specialist advice prior to urgent transfer to our centre. In these cases, date of diagnosis was taken as the date therapy was started and their baseline haemodynamic data were not included in analyses. 
3.2.1.2 Group 1 PAH
Patients were excluded from group 1 if the PCWP was >15mmHg.  Expanded haemodynamic criteria for PAH allowing PCWP ≤ 18mmHg have not been validated ADDIN EN.CITE [55, 56] and were not applied in order to augment the purity of the PAH cohort.  IPAH required the exclusion of other forms of PH by clinical evaluation and objective testing. Patients with heritable PAH or PAH in association with anorexigen or amphetamine use were considered to have IPAH as described elsewhere. ADDIN EN.CITE [101, 388, 389]  Patients with IPAH were excluded from the registry if FEV1 and/or FVC were consistently <60% predicted.  PAH-CHD was sub-classified in accordance with recent guidelines into 4 subgroups: Eisenmenger’s Syndrome, PAH associated with systemic-to-pulmonary shunts, PAH with small defects and PAH after corrective cardiac surgery ADDIN EN.CITE [6] (table 1).  Patients who had undergone Glenn shunt procedures were excluded as described elsewhere.[209]
3.2.1.3 Group 2 PH-LHD
Patients with PH-LHD were sub-classified on the basis of echocardiographic and MRI assessment of left ventricular function, valvular sufficiency, left atrial size and presence of left ventricular hypertrophy as described elsewhere. ADDIN EN.CITE [62, 390]  
3.2.1.4 Group 3 PH-Lung
In the presence of significant parenchymal lung disease on HRCT patients were diagnosed with PH-Lung as described previously, regardless of spirometry. ADDIN EN.CITE [292, 326] 

For the purposes of this study PH-COPD refers to patients with COPD as defined by post-bronchodilator FEV1/FVC ratio ≤ 0.7 where airflow obstruction was due to a combination of airway and parenchymal damage, as per NICE guidelines updated 2010[391] or significant emphysema. 
3.2.1.5 Group 4 CTPEH
Patients with CTEPH were referred to the multidisciplinary team at the United Kingdom national PEA centre, Papworth Hospital, Cambridge and assessment of surgical suitability was based on clinical condition, pulmonary haemodynamics and the appearances on at least 2 radiological modalities.  

For subgroup analysis, patients who were awaiting PEA at census were excluded because many were treated medically prior to surgery and thus could not be clearly assigned to a treatment group. 
3.2.1.6 Patients with connective tissue disease
PH-CTD may be present due to PAH, associated lung disease ADDIN EN.CITE [29, 392] or left heart disease. ADDIN EN.CITE [393, 394] ADDIN EN.CITE   Patients with CTD and significant lung or left heart disease were therefore sub-classified separately from groups 1, 2 and 3 to enable comparison of the full phenotypic range of PH-CTD.  In PH-CTD, an FVC <60% predicted or the presence of moderate or severe fibrosis (more than 1/3 of the lung fields involved) on HRCT were used as criteria to define lung disease associated PH (PH-Lung-CTD) as previously described. ADDIN EN.CITE [29, 392] ADDIN EN.CITE  
3.3 Investigations
3.3.1 Exercise Testing
Exercise capacity was assessed using the distance achieved during the incremental shuttle walking test (ISWD) according to the protocol of Singh et al[395] with the modification of allowing 1 catch up length lap if the patient is more than 0.5m away from the cone to prevent early termination of the test because of mis-timing.[396]  During the ISWT, the patient walks back and forth along a 10m course while keeping up with an externally paced signal which increases in frequency each minute.  Heart rate and oxygen saturation were continuously recorded during the test and the test was terminated if the patient felt unable to continue or failed to reach the turning point by the time of the next signal.
3.3.2 Pulmonary function testing
Pulmonary function test predicted normal values were obtained using European Community of Coal and Steel 1993 predicted equations.[397]

For patients with COPD, baseline ABGs results were collected for treatment-naïve patients in stability within 90 days of diagnosis, both on air and where multiple samples had been taken, on the highest entrained flow of oxygen.
3.3.3 Echocardiography
ECHOs were performed by sonnographers experienced in the assessment of PH.  SPAP was estimated by the modified Bernoulli equation with RAP usually assigned a value based on visual assessment of the diameter and respiratory variation of the inferior vena cava.
3.3.4 Right Heart Catheterisation
RHCs were performed with the patient supine breathing room air where tolerated.  A balloon-tipped 7.5 Fr Thermodilution catheter (Becton-Dickinson USA) was positioned using haemodynamic and fluoroscopic guidance and full sterile conditions observed.  Venous access was usually via the right internal jugular vein and real-time ultrasound guidance was used to locate the vessel.  CO was measured using the thermodilution method.  PVR in dyn.s.cm-5 was calculated according to the equation

PVR= (mPAP –PCWP) x 80
CO

Acute vasodilator challenge was performed with inhaled nitric oxide and contemporaneous definition of positive vasodilator response was used. ADDIN EN.CITE [146, 172] (table 6)  Gas in a concentration of 100ppm (British Oxygen Company) was delivered via nasal cannulae using a pulsatile (breath triggered) nitric oxide delivery system.  Nitric Oxide was administered for 5 minutes after which haemodynamic measures were repeated. No deaths or sustained morbidity resulted from baseline right heart catheterization.
3.3.5 CT scan
3.3.5.1 Computer tomography scan acquisition parameters
From 2006, a 64 slice multidetector CT scanner (Light-Speed General Electric Medical Systems, Milwaukee, WI) was used. CTPA was performed during a single breath-hold and acquisition parameters: 100mA with automated dose reduction, 120kV, pitch 1, rotation time 0.5s and 0.625mm collimation. The field of view was 400x400mm with an acquisition matrix of 512 x 512.  100ml of intravenous contrast agent (Ultravist 300; Bayer Schering, Berlin, Germany) was administered at a rate of 5ml/s.  The CTPA images were reconstructed using a soft filter to provide contiguous 0.625mm axial slices from the apex of the lung to the diaphragm for review.  1.25mm HRCT slices were also reconstructed every 10mm from the contrast enhanced acquisition using a high spatial resolution filter.  Prior to 2006, CTPA was performed using single slice scanners (CTi Hispeed and Hi speed Fxi, GE, Connecticut, USA).  A 100ml bolus of intravenous contrast (Ultravist 300; Bayer Schering, Berlin, Germany).  Acquisition parameters of 250mA, 120kVp, 1.4 pitch, 3mm slice thickness and 0.5s rotation time were used. 
3.3.5.2 CT scan measurements
For patients with PH-COPD, HRCT and CTPA scans were reviewed and scored as described below.
3.3.5.2.1 Lung Parenchyma measurements on CT scan
The degree of emphysema and any co-existing pulmonary fibrosis were assessed using HRCT scan independently evaluated by 2 chest radiologists blinded to clinical data and each other’s findings.  A visual scale based on previous studies ADDIN EN.CITE [270, 398, 399] was used to score degree of parenchymal abnormality in the upper, mid and lower zone of each lung (0=<5%, 1=5-25%, 2=26-50%, 3=51-75%, and 4=76-100%) for both emphysema and fibrosis.  In order to assess the distribution of parenchymal disease on HRCT for the purpose of this study, the sum of the right and left upper zone scores was compared to the sum of the right and left lower zone scores for emphysema and fibrosis respectively.  
3.3.5.2.2  Cardiac and major vessel measurements
Widest short axis diameter of the main pulmonary artery was measured and the corresponding transverse diameter of the ascending aorta was obtained. The maximum short axis diameter of the right and left ventricle were also measured in an axial plane. Left atrial size was assessed using the maximal left atrial antero-posterior dimension measured from axial CT slices.
3.4 Treatment
Treatment was in accordance with contemporaneous guidelines and national commissioning policies.[167, 400]  

Patients with a positive vasoreactivity test to nitric oxide, as defined by accepted practice at the date of RHC (table 6), were treated with CCBs. ADDIN EN.CITE [146, 172] ADDIN EN.CITE 

Table 6 Definition of a positive vasodilator response 

Time period	Definition
Prior to June 2004	Fall in mPAP or PVR ≥ 20% without a fall in CO ADDIN EN.CITE [145] ADDIN EN.CITE 
June 2004 onwards	A drop in mPAP by ≥ 10mmHg to a value ≤ 40mmHg with an unchanged or increased CO[401]

ERAs, PDE-5-Is and prostanoids (nebulised or intravenous iloprost or subcutaneous treprostinil) were used as monotherapy or in combination as clinically indicated.   The intravenous prostanoid used during the registry period was iloprost which, although not licensed for the treatment of PH, is commonly used in the United Kingdom. ADDIN EN.CITE [402]  This was initially due to lower cost, its superior stability and half-life compared to epoprostenol. Treprostinil is a stable prostacyclin analogue with similar pharmacological actions to epoprostenol but with the advantages of longer half-life and chemical stability at room temperature that permit delivery as a continuous subcutaneous infusion. ADDIN EN.CITE [403, 404]
Selected patients outwith groups 1 and 4 were treated with agreement of funding bodies. All patients were anticoagulated where indicated ADDIN EN.CITE [6] and referred for transplant assessment as appropriate.  Supplemental nocturnal or long-term oxygen therapy was prescribed as indicated. ADDIN EN.CITE [6]  The underlying medical conditions were diagnosed and managed by specialists in each field in accordance with contemporary medical practice.   The timing of follow-up visits was determined by clinical need.
3.5 Follow up
Patients were followed up until either their date of death, date of lung transplant or the censoring date 1st November 2010 for the whole cohort (chapter 5) and extended to 1st August 2011 for patients with PH-COPD (chapter 6).  Mortality status was ascertained via the National Health Service enhanced reporting service death report. Patients who were untraceable at census were deemed lost to follow up and excluded.   
3.6 Prognostic Factors
Prognostic factors for the cohort overall and for the subgroup with PH-COPD were also assessed.  Predictors of survival were investigated using multiple variable Cox regression analysis
3.7 Incidence Estimates
To assess the number of incident cases diagnosed at our centre with PAH, IPAH, PAH-CTD and CTEPH we assumed a stable referral population of 15 million people.  

This cohort includes highly selected patients in whom the elevation in PAP was thought to be out of proportion to the severity of underlying cardiac or respiratory thus triggering a referral to our supra-regional PH centre.  Therefore to estimate the incidence or prevalence of PH-Lung or PH-LHD in the general population from this cohort would be invalid.
3.8 Statistical Analysis
All statistical analysis was performed by JH with assistance from a senior colleague in the department.  All data was subject to standard tests of normality.  Continuous variables were described by mean (± standard deviation) or where nonparametric, median (interquartile range).  Multiple comparisons between groups were performed using analysis of variance for parametric data for multiple groups.  Comparisons between 2 groups were performed using independent T-test for parametric data and Mann-Whitney U test for nonparametric data.  Wilcoxon matched-pairs test was used to compare upper zone with lower zone emphysema and fibrosis scores on HRCT in chapter 6.  Categorical data are expressed as frequencies or proportions and were compared with the χ2 test.  Cohen’s kappa coefficient was used to test interobserver reliability with a Kappa of 1 indicating perfect agreement and 0 indicating agreement equivalent to chance.  

Censoring date was date of death or lung transplantation or in those patients surviving in follow-up censoring date was 1st November 2010 for the whole cohort (chapter 5) and extended to 1st August 2011 for patients with PH-COPD (chapter 6).  Event (death or transplantation)-free survival from date of diagnosis was estimated using the Kaplan-Meier method with comparison between groups performed by the Log-Rank test. 

Cox regression analysis was used to assess individual predictors of survival.  Variables with p-values of p ≤ 0.2 at univariate regression analysis were considered for multiple regression analysis performed using forward stepwise regression.  A p-value of <0.05 was deemed statistically significant throughout. Statistical analysis was performed using PASW Statistics v18 & v20 (SPSS, Chicago, Il).  

Receiver Operating Characteristics (ROC) curve analysis of survival at 2 years was used to derive threshold values for predictors of survival in PH-COPD.  The relationship between continuous variables was calculated using Pearson’s correlation test. 
3.9 Validation of Registry
The data contained in the ASPIRE registry was obtained from case notes and departmental databases with cross referencing to enhance accuracy wherever available.  On completion of the database, random samples of data were verified against source records and extensive checks were undertaken to ensure consistency and remove anomalous values.  In addition to documented clinical diagnoses, diagnostic group and subgroup were independently validated for the purpose of this study in over 950 cases by a consultant physician within the department.  Thirteen percent of patients were included in previously published registries. ADDIN EN.CITE [29, 69]
3.10 Data completeness
In the ASPIRE registry, baseline data was captured in >90% of cases for the vast majority of parameters. Only 2 variables had <90% completeness (CI in 87% and TLCO in 88%). 

Table 7 Completeness of baseline data in the ASPIRE registry

Data completeness for RHC variables is shown excluding patients with CHD where baseline RHC was not required for diagnosis.













Abbreviations; WHO, World Health Organisation functional class; ISWD, incremental shuttle walking distance; mRAP, mean right atrial pressure; mPAP, mean pulmonary arterial pressure; CI, cardiac index; PCWP, pulmonary capillary wedge pressure; SvO2; mixed venous oxygen saturation; TLCO, gas transfer.   
3.11 Study Limitations
The main limitation of this study is its observational nature involving retrospective collection of data generated during the course of routine clinical care from a single centre. However, the ability to exhaustively interrogate patient records and hospital databases has enabled remarkable data completeness.  Previous studies ADDIN EN.CITE [11] have demonstrated that cases managed by various centres can have significantly different characteristics and the results of our single centre study are not confounded by this because the cases were all assessed and managed by a dedicated, specialist multidisciplinary team with a uniform approach.  Haemodynamic data were required for inclusion except for the diagnosis of PAH-CHD, which is often made in childhood and RHC confirmation as part of assessment at a pulmonary vascular centre is not routine.  We therefore took the approach of other studies[209] and have not analysed RHC data for this group which would be incomplete.  

Generalisability of these results to patients seen in other centres has not been tested but in the diagnostic subgroups that have been well characterised in the literature, many similarities in baseline parameters and survival were noted.

Calculating disease incidence from registry data and an estimated referral population has obvious methodological limitations. Retrieval bias may have been introduced by retrospective data collection from notes with different levels of completeness.

Limitations of this study are further discussed in chapter 4, 5 and 6 as pertinent. 
3.12 Ethical Approval
















The clinical characteristics of the subgroups of pulmonary hypertension

This chapter is largely based on a paper published in the European Respiratory Journal “ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre” Hurdman, J et al Eur Resp J, 2012 39(4); 945-55.
Chapter 4: The clinical characteristics of the subgroups of pulmonary hypertension
4.1 Summary 

Rationale: PH is a heterogeneous condition.  To date no registry data exists reflecting the spectrum of disease across the 5 diagnostic groups 
Objectives: To describe and compare the demographic, clinical and haemodynamic characteristics of PH diagnostic groups and subgroups in a specialist referral centre.
Methods: Data was retrieved from hospital records for consecutive, treatment-naïve cases of PH diagnosed at the Sheffield Pulmonary Vascular Disease Unit between 1st February 2001 and 1st February 2010 using a cardiac catheter-based approach.  
Results: 1344 patients were enrolled, mean follow-up 2.9 years. Demographic and haemodynamic characteristics differed significantly between and within diagnostic groups.







PH is a heterogeneous condition ranging from a rare, rapidly progressive vasculopathy (IPAH) to more common and more minor elevations of pressure in the context of severe respiratory or cardiac disease. Improvements in our understanding of the mechanisms underlying PH have resulted in the evolution of a classification system which groups into categories diseases with shared pathophysiologial processes and is intended to guide the physician in predicting the natural history of disease and most appropriate form of treatment. The classification identifies 5 forms: Group 1-PAH, Group 2–PH-LHD, Group 3–PH-Lung, Group 4–CTEPH and Group 5 PH-miscellaneous. ADDIN EN.CITE [10]

The majority of studies in PH have focused on PAH and CTEPH but there is limited data comparing the characteristics of the subgroups of these major pre-capillary forms of PH in a contemporaneous cohort.  PAH can occur without known cause (IPAH) or in association with congenital heart disease or a number of systemic diseases including connective tissue disease, particularly SSc.  In PAH, a pulmonary arteriopathy leads to progressively increasing PVR resulting in right heart failure and early death. The emergence of targeted drug therapies since the late 1990’s for PAH and PEA as a definitive treatment for CTEPH revolutionised the previously limited options for patients. ADDIN EN.CITE [69, 166, 178]  Due to the rarity of these diseases, expense of therapies and required expertise, specialist PH centres (n=7) which adhere to nationally agreed standards of care ADDIN EN.CITE [32, 167] were first designated in the United Kingdom in 2001.  Importantly, the National Department of Health limits the prescription of therapies to these centres with an emphasis on the systematic and multi-modality evaluation of patients to centralise expertise and limit inappropriate prescription of high cost therapies.  





	To define the characteristics across all 5 diagnostic subgroups of PH.
	To compare other diagnostic subgroups to IPAH as a “gold standard” pulmonary vasculopathy.
	To review if demographics of patients seen in the current era at our centre are similar to those seen in registries from previous eras and other centres.
4.2.2 Hypothesis







Patient selection and data retrieval for the ASPIRE registry has been discussed earlier in chapter 3.  In summary, all consecutive patients undergoing assessment of suspected PH between February 2001-2010 were identified prospectively and were followed to 1st November 2010.   All patients underwent a standard, systematic diagnostic evaluation and diagnostic classification was by standard criteria following multidisciplinary assessment by experienced pulmonary vascular physicians and specialist radiologists.  

In 2010, a detailed review of departmental databases and hospital records was performed.  Pulmonary function tests and WHO functional class obtained closest to date of RHC were recorded as baseline measures. Exercise capacity was assessed using the distance achieved during the ISWT.[395] Patients were excluded if PH was attributable to multiple factors in unrelated diagnostic groups.  Date of diagnosis was taken as date of first RHC showing PH, except in patients with Eisenmenger’s Syndrome in whom RHC is not routinely required[209], where date of diagnosis was taken as date first seen at our centre. A small number of patients (n=5) commenced targeted therapy on specialist advice prior to urgent transfer to our centre. In these cases, date of diagnosis was taken as the date therapy was started and their baseline haemodynamic data were not included in analyses. 

PH-CTD may be present due to PAH, associated lung disease ADDIN EN.CITE [29, 392] or left heart disease. ADDIN EN.CITE [393, 394]  Patients with CTD and significant lung or left heart disease were therefore sub-classified separately from groups 1, 2 and 3 to enable comparison of the full phenotypic range of PH-CTD.  In PH-CTD, an FVC <60% predicted or the presence of moderate or severe fibrosis (more than 1/3 of the lung fields involved) on HRCT were used as criteria to define lung disease associated PH (PH-Lung-CTD) as previously described. ADDIN EN.CITE [29, 392] 
Outside IPAH the prognosis will depend not only on severity of PH but also the severity of underlying conditions.  Therefore IPAH was considered the gold standard disease and used as the referent group to which all other diagnostic subgroups were compared.  
The census point was date of death or lung transplantation or 1st November 2010 in those with event-free survival. Patients who were untraceable at census (n=4) were deemed lost to follow up and excluded.  
4.3.2 Statistical Analysis

















Figure 8 Study Cohort


RHC, right heart catheterisation; IPAH, idiopathic PAH; SSc, systemic sclerosis; CTD, connective tissue disease; CHD, congenital heart disease; PVOD, pulmonary veno-occlusive disease; LHD, left heart disease; ILD, interstitial lung disease; PEA, pulmonary endarterectomy.  Patients with PH on exercise in CTD had mPAP <25mmHg at rest and ≥30mmHg on exercise






Table 8  Baseline characteristics for the 5 diagnostic groups



















   None	28	11	87	51	14	28
   CCB 	1	2	1	2	1	0
   Oral monoRx 	46	49	12	39	65	31
   Oral comb	8	13	0	3	6	13
   Prostanoid monoRx	8	10	0	2	12	22
   Prostanoid comb	9	15	0	3	2	6
Abbreviations; WHO, World Health Organisation functional class; ISWD, incremental shuttle walking distance; mRAP, mean right atrial pressure; mPAP, mean pulmonary arterial pressure; CI, cardiac index; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; SvO2; mixed venous oxygen saturation, TLCO, gas transfer; CCB, calcium-channel blocker; oral monoRx, oral monotherapy; oral comb, combination phosphodiesterare-5-inhibitor and endothelin receptor antagonist; Prostanoid monoRx, prostanoid monotherapy; Prostanoid comb, prostanoid in combination with any other targeted therapy(s).






4.4.2 Group 1: PAH
Analysis of baseline characteristics demonstrated differences between the subcategories within group 1. Noticeably, patients with PAH-SSc had less severe haemodynamics but lower TLco than patients with IPAH, while those with PAH-CHD were younger (table 9). Within the combined IPAH group, 6 patients (3%) had heritable PAH, 4 (2%) had a history of amphetamine or anorexigen exposure, while 6% had a positive vasodilator response to nitric oxide during RHC.  Twenty-nine (15%) patients with PAH-CHD had Down’s syndrome. 


Table 9 Baseline characteristics for Group 1: Pulmonary Arterial Hypertension
	

















Abbreviations see table 8
* p<0.05 in comparison to IPAH, † p<0.05 in comparison to SSc, ‡ p<0.05 in comparison to CTD not SSc, § p<0.05 in comparison to Porto-pulmonary, || p<0.05 in comparison to all CHD, # p<0.05 in comparison to Eisenmenger’s


4.4.2.1	Age at diagnosis in IPAH
Within the idiopathic group, 115 (66%) patients were over the age of 50 years and 56 patients (32%) were over the age of 65 years at the time of diagnosis.  Patients over 50 years of age at the time of diagnosis exhibited poorer gas transfer and resting oxygen saturations despite equivalent spirometry and similar markers of right heart function (RAP and CI) compared to those patients diagnosed with IPAH under the age of 50 years at diagnosis.  The mPAP was lower and PCWP higher in those of greater age at diagnosis.    There was less female preponderance and fewer patients with positive response to vasoreactivity testing in the older group (table 10).


Table 10 Baseline characteristics for Idiopathic Pulmonary Arterial Hypertension by age at diagnosis



















Abbreviations see table 8


4.4.3 Group 2: PH-LHD
Patients with PH-LHD had relatively well maintained cardiac output and milder elevation of PVR but had higher RAPs compared to IPAH (table 10). In PH secondary to valvular heart disease (PH-LHD-Valvular), comprising 22 mitral, 4 aortic, 16 mixed mitral/aortic significant valvular abnormalities.  Thirty-six percent of patients with PH-LHD-Valvular had undergone valve replacement.  
Table 11 Baseline characteristics for group 2; pulmonary hypertension due to left heart disease

	IPAH	LV systolic dysfunction	LV diastolic dysfunction	ValvularDisease















IPAH data shown for comparison. Abbreviations see table 8; LV, Left Ventricular
* p<0.05 in comparison to LV systolic dysfunction, † p<0.05 in comparison to LV diastolic dysfunction, ‡ p<0.05 in comparison to valvular disease, § p<0.05 in comparison to IPAH
4.4.4 Group 3: PH-Lung

In PH-COPD, a moderate elevation in PVR but significant reduction in TLCO was observed (table 12).  This subgroup is studied in detail in chapter 6.

Table 12 Baseline characteristics for group 3; pulmonary hypertension due to lung disease and/or hypoxia

	IPAH	COPD	ILD	Sleep disorders &  Alveolar hypoventilation















IPAH data shown for comparison. Abbreviations see table 8
* p<0.05 in comparison to COPD, † p<0.05 in comparison to ILD, ‡ p<0.05 in comparison to sleep/alveolar hypoventilation, § p<0.05 in comparison to IPAH


4.4.5 Group 4: CTEPH
Two hundred and forty-two patients were diagnosed with CTEPH.  In 4 cases, confident delineation of disease distribution was impossible due to sub-optimal imaging which could not be repeated. At census date, 20 patients had not undergone planned PEA and were excluded from further analysis.  (figure 9) Therefore there were 108 patients with proximal disease undergoing PEA, 58 with surgically inaccessible CTEPH and 52 patients with unoperated surgically accessible CTEPH.  There was no significant difference in hemodynamic severity between these groups (table 13).  Eighty-nine (82%) of 108 patients who underwent PEA received bridging pulmonary vascular therapy (69 oral monotherapy and 20 prostanoid-based therapy). 

Figure 9 Patients with CTEPH


Table 13 Baseline characteristics for group 4; chronic thromboembolic pulmonary hypertension

	IPAH	CTEPH operated	CTEPH not operated	CTEPH not surgically accessible















IPAH data shown for comparison. Abbreviations see table 8
* p<0.05 in comparison to Proximal operated, † p<0.05 in comparison to proximal not operated, ‡ p<0.05 in comparison to distal, § p<0.05 in comparison to IPAH


4.4.6 Group 5: PH-miscellaneous
Thirty-two patients were diagnosed with PH in the subcategories of group 5.  PH associated with sarcoidosis was most common (n=14). Detailed interpretation of baseline data for patients in group 5 was not performed due to limited numbers.
4.4.7 PH-CTD
In total 323 patients with PH-CTD met inclusion criteria; 188 with isolated PAH, 102 with PH-Lung-CTD and 33 with PH-CTD associated with LHD (PH-LHD-CTD).  In isolated CTD-PAH, SSc was the most frequent underlying CTD, present in 156 (83%) patients. SSc was of the limited cutaneous form in 94% of these cases. Thirty-two patients without SSc were diagnosed with isolated PAH-CTD including 9 patients with undifferentiated CTD, 7 SLE, 6 with overlap CTD, 5 with mixed CTD, 3 with RA, and 2 patients with Sjögren’s syndrome.  In patients with CTD other than SSc, the majority of PH was associated with parenchymal lung disease. 













Table 14 Characteristics of patients with CTD diagnosed with PH by year of diagnosis.

	2001n=8	2002-6n-130	2006-10n=185	p value2002-6 v 2006-10
Systemic Sclerosis %	100	73	69	0.21
3 Year Survival all PH (%)	38	46	56	0.11
3 year Survival PAH (%)	60	47	63	0.09
Age (yrs)	65 ± 8	62 ± 13	63 ± 13	1.00
Female (%)	100	83	83	0.93
WHO Class III-IV (%)	75	91	82	0.34
Baseline ISWT (m)	151 ± 94	129 ± 114	148 ± 125	0.57
mRAP (mmHg)	4 ± 4	8 ± 6	9 ± 5	0.39
mPAP (mmHg)	37 ± 8	41 ± 11	42 ± 12	0.79
PCWP (mmHg)	4 ± 3	10 ± 5	11 ± 6	0.05
PVR (dyn.s.cm-5)	636 ± 336	621 ± 387	578 ± 395	1.0
CI (L.min.m-2)	2.40 ± 0.59	2.82 ± 0.94	2.98 ± 0.83	0.43
SvO2 (%)	62 ± 5	65 ± 9	65 ± 9	1.00
FEV1 (%)	82 ± 16	74 ± 21	74 ± 21	1.00
TLCO (%) 	34 ± 8	39 ± 13	41 ± 14	0.26
PAH:PH-Lung (%)	63:37	68:27	51:35	0.04

Abbreviations see table 8.  Only the 323 patients who met inclusion criteria for the ASPIRE registry were used in the comparison of baseline demographics and haemodynamics.


4.4.8 Incidence of Pulmonary Hypertension
The number of incident cases increased throughout the study period from 25 in 2001 to 271 in 2009. Assuming a stable referral population of 15 million, between 2001-09 the incidence of patients diagnosed at our centre with PAH increased from 0.9 to 6.1, IPAH from 0.3 to 2.1, PAH-CTD from 0.3 to 2.4 and CTEPH from 0.3 to 3.7 cases/million/year respectively.
4.4.9 Idiopathic Registry Criteria





To our knowledge, this is the first study involving comparison between all diagnostic groups of a large cohort of consecutive cases of PH identified at a specialist centre.  All patients were treatment-naïve at entry and diagnosis was made at RHC (with the exception of selected patients with CHD). Importantly, this study provides detailed phenotypic information on consecutive, incident cases in the major subgroups of PAH and CTEPH and highly selected, consecutive patients with PH-LHD and PH-Lung referred for assessment of suspected severe PH. The results demonstrate the differences between these distinct groups of patients with PH attending a specialist PH centre and highlight the need for precise characterisation. 
4.5.1 Group 1 
There are several clinically important findings from our cohort regarding the previously well-described diagnostic group 1. As seen in other registries, there was a high degree of functional impairment at diagnosis suggesting delay between onset of symptoms and diagnosis. ADDIN EN.CITE [11, 91]  It is also noteworthy that even in conditions such as SSc, where screening for PH with ECHO to allow earlier management is recommended (figure 2), the majority of patients were in class III or IV at diagnosis.  In other countries, it has been hypothesised that the wide availability of oral targeted pulmonary vascular therapies may delay referral to specialist centres. ADDIN EN.CITE [11]  However in the United Kingdom the tight regulation of prescription of all targeted pulmonary vascular therapies should negate this effect. 

Many additional findings regarding PAH concur with those previously described. ADDIN EN.CITE [11, 31, 55, 238, 246]  The proportion of patients with IPAH with a positive vasodilator response (6%) was of a similar order to that in previous registries. ADDIN EN.CITE [11, 238]  However, there were fewer cases of anorexigen associated PAH compared to the French National Registry were they made up 9.5% of patients with PAH. ADDIN EN.CITE [11]  The number of cases of PAH-CTD associated with CTDs other than SSc was small. ADDIN EN.CITE [29, 168, 405-409]  Also in contrast to the French registry, at our centre a much higher proportion (31% v 15%) of patients with PAH had an underlying connective tissue disease and limited cutaneous SSc was far more common than the diffuse form (94% v 67% of PAH-CTD-SSc). ADDIN EN.CITE [11]  The proportion of patients with PH-CTD with LHD was also lower.  These differences may reflect varying approaches to screening, referral criteria and diagnostic strategies. In studies, screening for PAH-CTD has enabled detection of mild PAH. ADDIN EN.CITE [132]  Implementing a screening programme for PAH-CTD was associated with an increase in patients evaluated and diagnosed. However, haemodynamic severity at diagnosis remained unchanged.  The recently published DETECT algorithm for detection of PAH in SSc uses a TLco <60%, SSc duration >3years and two ECHO parameters (RA area and velocity of Tricuspid regurgitation) to determine the need to proceed to RHC.[33]  This had only a 4% false negative rate compared to a 29% of diagnoses missed if using the European Society of Cardiology guidelines. ADDIN EN.CITE [6, 33]  Updating our unit’s screening recommendations in light of the findings of the DETECT study may achieve earlier diagnosis.  However, the performance of the DETECT screening tool outwith clinical trials is yet to be prospectively validated.

Age at diagnosis in IPAH has increased from 34 years in the NIH registry to 55±16 years in our cohort, in keeping with other observations. ADDIN EN.CITE [11, 91, 238, 389]  Notably the proportion of  patients with PAH associated with HIV was lower than observed elsewhere ADDIN EN.CITE [11, 238, 244] which may be related to a lower prevalence of HIV in the United Kingdom[410], differing epidemiological factors in HIV acquisition​[13]​ and possibly reduced awareness of PAH in physicians managing HIV.
4.5.2 Group 2 and 3
Several significant observations regarding patients identified at a specialist referral centre with Group 2, PH-LHD and Group 3, PH-Lung were made. Apart from significantly elevated right atrial pressures patients with PH-LHD had less severe pulmonary haemodynamic abnormalities compared to IPAH including only modest increases in PVR.  In the PH-lung group, those patients with sleep disordered breathing or alveolar hypoventilation had significantly higher cardiac indices compared to those with parenchymal or airways disease.  Many patients with PH-lung could have been misclassified as IPAH in the absence of thorough clinical assessment and review of lung parenchyma on HRCT.  This emphasizes the need for adequate investigation of patients with severe unexplained PH, particularly assessment with RHC, appropriate radiology and overnight oximetry, to ensure patients with PH-LHD or PH-Lung are not misdiagnosed as IPAH resulting in inappropriate management.  
4.5.3 Group 4
The haemodynamics features of CTEPH were similar whether surgically accessible or inaccessible.  Interestingly, when compared to IPAH, surgically inaccessible CTEPH was seen in older patients with less female predominance and haemodynamic parameters were less severely affected with TLco better preserved.
4.5.4 Incidence and prevalence
The observed incidence of diagnosed PAH and CTEPH increased markedly during the study period in keeping with increased awareness of these conditions. The incidences at the end of the study period are comparable to those observed in other large registries and are indicative of the success of the United Kingdom PH network. ADDIN EN.CITE [11, 69, 238, 246] 
4.5.5 Study Limitations
Many of the limitations of this study are discussed in section 3.11.  An important caveat is that this cohort comprises and thus reflects the population of patients referred to a supra-regional pulmonary vascular unit with unexplained PH or in whom the elevation in pulmonary artery pressure was thought to be out of proportion to the severity of the underlying cardiac or respiratory disease. Therefore, it is not representative of all patients with PH-LHD and PH-Lung. Although PH-LHD-Diastolic was the commonest form of PH-LHD in our registry, it is generally thought that PH-LHD-Systolic is more common in the population as a whole, but is referred infrequently to a specialist centre as a diagnosis of IPAH is less likely to be considered. Similarly, the PH-Lung patients within this registry represent a skewed sample since in the majority of patients with PH associated with respiratory disease the PH is mild (cor pulmonale) and is not referred for further assessment. Although the numbers of patients with PH-LHD and PH-Lung were smaller than with PAH and CTEPH in our registry, in the population as a whole the numbers of patients with PH-LHD and PH-lung are clearly significantly higher. 

Haemodynamic data were required for inclusion except for the diagnosis of PAH-CHD, which is often made in childhood.  A further limitation of this study is the lesser number of patients in some groups such as PAH-HIV and the subgroups of group 5.  Larger studies are required to further define the survival and characteristics of these groups.  

Although this data was collected from a single centre our unit serves a population of over 15 million and receives referrals across the whole clinical spectrum of PH and this study cohort is representative of the patients seen in a tertiary pulmonary vascular service with no selection bias.  
4.6 Conclusion
In conclusion, the ASPIRE registry describes baseline characteristics for a large cohort of consecutive, treatment-naïve patients referred for evaluation of suspected PH at a specialist PH centre.  Adequate systematic assessment of suspected PH is key to accurate classification and appropriate patient management. 

















Outcomes and predictors of survival in pulmonary hypertension and its sub-groups

This chapter is largely based on a paper published in the European Respiratory Journal “ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre” Hurdman, J et al Eur Resp J, 2012 39(4); 945-55.
Chapter 5 Outcomes and predictors of survival in pulmonary hypertension
5.1 Summary 

Rationale: Pulmonary vascular disease specialist centres increasingly evaluate patients across all 5 diagnostic groups.  Comparative survival across the common groups of PH has not been well characterised in the modern treatment era and predictors of survival across all groups have not been previously described.
Objectives: To investigate the survival and prognostic factors of PH in the modern treatment era.
Methods: Data was retrieved from hospital records for consecutive, treatment-naïve cases of PH diagnosed at the Sheffield Pulmonary Vascular Disease Unit between 1st February 2001 and 1st February 2010 using a cardiac catheter-based approach. 
Results: 1344 patients were diagnosed with PH with mean follow-up 2.9years. Three-year survival was 68% for PAH, 73% for PH-LHD, 44% for PH-Lung, 71% for CTEPH and 59% for PH-Miscellaneous.  Compared with PAH, survival was inferior in PH-Lung and superior in CTEPH (p<0.05).  Multivariate analysis demonstrated that diagnostic group independently predicted survival. Within PAH, Eisenmenger’s PAH-CHD survival was superior to IPAH which was superior to PAH-SSc (p<0.005). Within PH-Lung, 3-year survival in sleep disorders/alveolar hypoventilation (90%) was superior to PH-Lung with COPD (41%) and ILD (16%)(p<0.05). In CTEPH, long-term survival was best in patients with surgically accessible disease undergoing PEA. 






PH is highly heterogeneous, encompassing a broad spectrum of diseases.  Greater understanding of underlying mechanisms resulted in the evolution of a classification system grouping diseases with shared pathophysiology with the intention of predicting the natural history of disease and guiding treatment.  The classification in use at the time of this study is shown in figure 1. ADDIN EN.CITE [10]  Prior to the development of new therapies during 1990s, the mean life expectancy at diagnosis in IPAH was 2.8 years ADDIN EN.CITE [91] and this devastating disease continues to have a life expectancy worse than many forms of cancer.  

The majority of studies in PH have focused on PAH and CTEPH but there is limited data comparing outcome in the subgroups of these major pre-capillary forms of PH in a contemporaneous cohort.  The emergence of targeted drug therapies since the late 1990’s for PAH and PEA as a definitive treatment for CTEPH revolutionised the previously limited options for patients. ADDIN EN.CITE [69, 166, 178] ADDIN EN.CITE   As previously described in section 4.2 in 2001 in the United Kingdom seven specialist PH centres were designated.    





	To define the outcomes and prognostic markers across all 5 diagnostic subgroups of PH.
	To assess if PH diagnostic group influences survival.
	To review if outcomes of patients seen in the current era at our centre are similar to those seen in registries from previous eras and other centres.
5.2.2 Hypotheses
	Survival will differ significantly between diagnostic groups.
	Survival in the modern treatment era will have improved compared to historic series.
	Survival will differ significantly between subgroups within diagnostic groups.
	Survival in CTEPH will be superior in patients undergoing PEA surgery.
	Patients with CTD may develop different forms of PH and survival will vary between these.






Patient selection and data retrieval for the ASPIRE registry has been discussed earlier in chapter 3 and the ASPIRE study cohort is shown is figure 8.  

In summary, all consecutive patients undergoing assessment of suspected PH between February 2001-2010 were identified prospectively and were followed to 1st November 2010.  All patients underwent a standard, systematic diagnostic evaluation and diagnostic classification was by standard criteria following multidisciplinary assessment by experienced pulmonary vascular physicians and specialist radiologists.  

In 2010, a detailed review of departmental databases and hospital records was performed.  Pulmonary function tests and WHO functional class obtained closest to date of RHC were recorded as baseline measures. Exercise capacity was assessed using the distance achieved during the ISWT.[395]   Patients were excluded if PH was attributable to multiple factors in unrelated diagnostic groups.  Date of diagnosis was taken as date of first RHC showing PH, except in patients with Eisenmenger’s Syndrome in whom RHC is not routinely required[209] where date of diagnosis was taken as date first seen at our centre. A small number of patients (n=5) commenced targeted therapy on specialist advice prior to urgent transfer to our centre. In these cases, date of diagnosis was taken as the date therapy was started and their baseline haemodynamic data were not included in analyses.  As previously detailed, patients with CTD and significant lung or left heart disease were therefore sub-classified separately from groups 1, 2 and 3 to enable comparison of the full phenotypic range of PH-CTD.  
5.3.2 Treatment and follow up
Treatment was in accordance with contemporaneous guidelines and national commissioning policies.[167, 400]  Patients with a positive vasoreactivity test to nitric oxide, as defined by accepted practice at the date of RHC, were treated with CCBs. ADDIN EN.CITE [146, 172]  ERAs, PD-5-Is and prostanoids (nebulised or intravenous iloprost or subcutaneous treprostinil) were used as monotherapy or in combination as clinically indicated. All patients were anticoagulated where indicated ADDIN EN.CITE [6] and referred for transplant assessment as appropriate.  
The census point was date of death or lung transplantation or 1st November 2010 in those with event-free survival. Patients who were untraceable at census (n=4) were deemed lost to follow up and excluded.  
5.3.3 Statistical Analysis




1737 consecutive patients were evaluated for suspected PH using a RHC-based approach and 1344 incident cases of PH were identified as shown in (figure 8). 

During follow-up, 521 (39%) patients died and 8 (1%) patients underwent lung transplantation. The maximal duration of follow up was 9.7 years with a mean follow-up of 2.9 (±2.1) years.  Therapeutic strategies changed over the study period as a result of an increase in available therapies and changing contemporaneous clinical guidelines and prescribing agreements. Selected patients outwith groups 1 and 4 were treated with agreement of funding bodies. 
5.4.1 Survival by diagnostic group






Figure 11 Cumulative survival from date of diagnosis in pulmonary hypertension by diagnostic group 


	        157     132       97      55      33       18		Group 2 PH-LHD
                     242     206      137     97      73       51		Group 4 CTEPH
                     598     501     382    269    182     119		Group 1 PAH
                       32       26        15     10       8         6 	 	Group 5 PH-Miscellaneous
	        178     124       66      41      31       18		Group 3 PH-Lung
	       1207    989      697   472     327    212		Total


5.4.2 Survival within diagnostic groups
5.4.2.1 Group 1: PAH
Three-year survival in IPAH was 63%, poorer than in PAH-CHD (85%) but significantly better than PAH-SSc (52%) (p<0.01; figure 11).  
Figure 12 Cumulative survival from date of diagnosis in group 1 pulmonary arterial hypertension


	       
	        108       98      85     67      46      32		PAH-Eisenmenger’s        
                   175     143    102     67      44      30		IPAH
	        156     123      83     51      31      14		PAH-SSc
	         439     364    270   185     121     76	Total
Marked improvement in the outcomes of patients with IPAH were noted when the actual survival of the idiopathic cohort was compare to that predicted for this cohort by the NIH survival equation published in 1991 (table 15). ADDIN EN.CITE [91]  In addition survival in younger patients with IPAH was superior to that in patients over the age of 50 years at diagnosis (figure 12).
Table 15 Survival in Idiopathic PAH compared to that predicted by the NIH equation

	Predicted survivalusing NIH equation %	Actual Survival  All IPAH %	Survival in patients <50years of age at diagnosis %
1 year from diagnosis	69	86	97
2 years from diagnosis	57	74	93




Figure 13 Cumulative survival from date of diagnosis in idiopathic pulmonary arterial hypertension by age at diagnosis

 
    	     60	     55	     42	    28	   18	  13	Age at diagnosis under 50 yrs
	   115	     88	     60	    39	   26	  17	Age at diagnosis above 50 yrs
	   175	   143	   102	    67	   44	  30	Total 
5.4.2.2 Group 2: PH-LHD
There was no significant difference in outcome between patients with diastolic or systolic left ventricular dysfunction although the numbers in the latter group were small. Survival in PH-LHD-valvular was significantly worse than in PH secondary to diastolic dysfunction (PH-LHD-Diastolic) (p=0.001; figure 13). 


Figure 14 Cumulative survival from date of diagnosis in group 2 pulmonary hypertension associated with left heart disease


	    
 	      17	    14    10      5      4      2 		PH-LHD-Systolic
 	      98     84    65    37    21    12		PH-LHD-Diastolic 
	      42     34    22    13      8     4		PH-LHD-Valvular 





Survival in patients with PH-LHD-Diastolic was superior to patients with IPAH with 3 year survival 80% versus 63% respectively (p=0.001; figure 14).

Figure 15 Cumulative survival from date of diagnosis in pulmonary hypertension associated with diastolic left heart disease versus idiopathic pulmonary arterial hypertension


	    
 	      98       84      65      37      21      12		PH-LHD-Diastolic 
	     175     143    102     67      44      30		IPAH 
	    273      227    167    104     65      42		Total 

5.4.2.3 Group 3: PH-Lung
Survival in patients with PH-Lung was dependent on subgroup. Three-year survival in PH associated with sleep disordered breathing/alveolar hypoventilation (90%) was markedly better than PH-COPD (41%, p=0.001) which in turn was better than PH-ILD (16%, p=0.011; figure 15). 
Figure 16 Cumulative survival from date of diagnosis in group 3 pulmonary hypertension associated with lung disease and /or hypoxia


                 25     23    20    14    10      7		PH-Sleep/hypoventilation  
	     101    72    33    20    16      9		PH-COPD
	       32    17      7      2      2      0		PH-ILD
	     158   112   60    36    28    16		Total
5.4.2.4 Group 4: CTEPH








  	    108   101    75    55    42    32	CTEPH operated
                 52     45    27    19    17    10	CTEPH not operated
                 58     51    34    23    14      9	CTEPH not surgically accessible





Figure 18 Cumulative survival from date of diagnosis in group 4 chronic thromboembolic pulmonary hypertension patients with surgically accessible CTEPH not undergoing PEA by reason not operated
(*2 patients were excluded because it was unclear whether PEA was not undertaken primarily due to comorbidities or patient choice)
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               13    10     4      2      1     1		Comorbidities




5.4.2.5 Group 5: PH-miscellaneous
Thirty-two patients were diagnosed with PH in the subcategories of group 5.  PH associated with sarcoidosis was most common (n=14) with 3-year survival 63%.  Detailed interpretation of survival for patients in group 5 was not performed due to limited numbers.
5.4.3 PH-CTD
In total 323 patients with PH-CTD met inclusion criteria; 188 with isolated PAH, 102 with PH-Lung-CTD and 33 with PH-LHD-CTD.    Survival in PAH-CTD associated with SLE was superior when compared to other groups (p<0.02). Three-year survival in PH-LHD-CTD (73%) was significantly better than in PAH-CTD (54%) and PH-Lung-CTD (40%) (p<0.05; figure 18). 


Figure 19 Cumulative survival from date of diagnosis in connective tissue disease by category of pulmonary hypertension


	       33     26      15     9       4       4	PH-LHD-CTD
	     188   148    100    64     38    20	PAH-CTD
                102     76      44    24     12      8	PH-Lung-CTD
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5.4.4 Common forms of PH seen in clinical practice
Six forms of PH comprised the majority (82%) of diagnosed cases of PH in clinical practice: IPAH, PAH-SSc, PAH-CHD, PH-LHD, PH-Lung and CTEPH. Comparative survival of these 6 groups is shown in figure 19.

Figure 20 Cumulative survival from date of diagnosis in 6 most common forms of pulmonary hypertension

	  
               198   179   156   122    90    64		PAH-CHD
	    157   132     97     55    33    18		PH-LHD
	    242   206   137     97    73    51		CTEPH  
               175   143   102     67    44    30		IPAH
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               156   123     83     51    31    14		PAH-SSc
             1106   907   641   433   302  195	Total

5.4.5 Predictors of survival in PH








Groups 1 & 2Age:    per yearCI:       per L/min/m2WHO:  I/II            III/IVGroup: 1            2Groups 1 & 3Age:     per yearCI:       per L/min/m2WHO:  I/II            III/IVGroup: 1            3Groups 1 & 4Age:     per yearCI:       per L/min/m2WHO:  I/II            III/IVGroup: 1            4	1.03 (1.03, 1.04)0.71 (0.59, 0.84)Reference2.73 (1.89, 3.93)Reference0.74 (0.52, 1.03)1.04 (1.03, 1.05)0.67 (0.58, 0.78)Reference2.78 (1.93, 4.00)Reference2.00 (1.57, 2.54)1.03 (1.03, 1.04)0.71 (0.60, 0.84)Reference2.32 (1.61, 3.34)Reference0.77 (0.59, 1.00)	<0.001<0.001<0.0010.077<0.001<0.001<0.001<0.001<0.001<0.001<0.001<0.05	1.03 (1.02, 1.05)0.72 (0.60, 0.86)Reference1.94 (1.23, 3.06)Reference0.48 (0.33, 0.72)1.03 (1.02, 1.04)0.66 (0.54, 0.78)Reference1.77 (1.12, 2.80)Reference1.32 (1.01, 1.72)1.03 (1.02, 1.04)0.66 (0.55, 0.79)Reference1.62 (1.02, 2.57)Reference0.42 (0.32, 0.57)	<0.001<0.001<0.005<0.001<0.001<0.001<0.05<0.05<0.001<0.001<0.05<0.001
Abbreviations; HR, hazard ratio; CI, cardiac index. Data presented as HR (95% confidence interval). Group1, PAH; Group 2, PH-LHD; Group 3, PH-Lung; Group 4, CTEPH
5.5 Discussion

This study reports the findings of a large cohort of consecutive cases of PH identified at a specialist centre.  All patients were treatment-naïve at entry and diagnosis was made at RHC (with the exception of selected patients with CHD). Importantly, this study provides detailed prognostic information on consecutive, incident cases in the major subgroups of PAH and CTEPH and highly selected, consecutive patients with PH-LHD and PH-Lung referred for assessment of suspected severe PH. The results demonstrate the differences between these distinct groups of patients with PH attending a specialist PH centre and highlight the need for precise characterisation.
5.5.1 Survival
As expected, there was a marked difference in survival between the 3 commonest forms of Group 1 (Eisenmenger’s, IPAH and PAH-CTD), likely related to differences in demographic characteristics such as age, the ability of the right ventricle to cope with increased afterload and severity of the underlying pulmonary vasculopathy. ADDIN EN.CITE [411, 412]  In the CTEPH group, patients with operable disease who underwent PEA had the best long-term outcome, confirming the importance of appropriate operative intervention. We have also shown that CTEPH patients with operable disease considered too mild to warrant PEA had an excellent survival. Patients with surgically accessible disease who did not proceed to PEA because of co-morbidities had poorer survival than those with operable disease who chose to be treated medically. Overall patients with unoperated surgically accessible CTEPH had similar outcomes to patients with disease of a surgically inaccessible distribution. This emphasises the importance of effective identification and counselling of patients with potentially operable CTEPH. In patients with a high pre-test probability of PAH such as CTD, we have demonstrated the importance of identifying the type of PH as it influences prognosis. In CTD, those with PH-LHD-CTD have a significantly improved survival compared to PAH-CTD and PH-Lung-CTD.  

Many additional findings regarding PAH and CTEPH concur with those previously described. ADDIN EN.CITE [11, 29, 31, 55, 69, 238, 246]  As observed elsewhere, survival in PAH-SSc was inferior to that of IPAH and of PAH-SLE. ADDIN EN.CITE [29, 239, 413]  Survival in IPAH, PAH-SSc and CTEPH were superior to that described in historical series. ADDIN EN.CITE [27, 70, 71, 91, 112]   In addition, observed survival in IPAH was markedly improved compared to that predicted by the NIH equation especially in the younger patient group (<50 years) with an age range more akin to that in the early registries. ADDIN EN.CITE [91] ADDIN EN.CITE   This suggests a true improvement in mortality.  The reasons behind poorer outcomes in older patients with IPAH remain unclear; perhaps IPAH in the elderly is a different form of the disease less amenable to current therapies or has different pathophysiology as supported by the increase in the proportion of males in this older group.  Alternatively it may be the increased burden of co-morbidities in this group of older patients with IPAH that reduces survival.[56] 

Several significant observations regarding patients identified at a specialist referral centre with Group 2, PH-LHD and Group 3, PH-Lung were made. Apart from significantly elevated right atrial pressures patients with PH-LHD had less severe pulmonary haemodynamic abnormalities compared to IPAH This observation has recently been described elsewhere[414]; however we were also able to define long term survival in this patient group. In particular, in patients with PH-LHD-Diastolic survival is greatly superior to IPAH.  In the PH-lung group, those patients with sleep disordered breathing or alveolar hypoventilation demonstrated superior outcomes compared to those with parenchymal or airways disease.  This emphasizes the need for adequate investigation of patients with severe unexplained PH, particularly assessment with RHC, appropriate radiology and overnight oximetry, to ensure patients with PH-LHD or PH-Lung are not misdiagnosed as IPAH resulting in inappropriate prognostication.  

Again, an important caveat is that this cohort comprises patients referred to a supra-regional pulmonary vascular unit with unexplained PH for consideration of targeted pulmonary vascular therapy.  Therefore, it is not representative of all patients with PH-LHD and PH-Lung in general. Importantly however, our findings provide prognostic information to inform clinicians counselling patients with more severe pulmonary hypertension in the context of left heart disease and lung disease.  
5.5.2 Incident cases
A small number of previous studies have compared outcomes between selected different forms of PAH ADDIN EN.CITE [238, 239] while national registries have either focused on a single PH group or PAH subtype. ADDIN EN.CITE [29, 55, 69, 91, 237, 246]  A single study previously compared outcomes of groups 1, 3 and 4 but enrolled only 222 patients while the methodology was unclear. ADDIN EN.CITE [280]  A recognised criticism of several previous registries is the fact that the majority of patients included were prevalent cases (i.e. had been diagnosed prior to enrolment). ADDIN EN.CITE [11, 31, 113, 238, 243, 250] ADDIN EN.CITE   It has recently been demonstrated that prevalent cases of PAH have more stable disease with superior outcomes compared with incident cases.  Thus it is possible that registries which include prevalent patients give a less reliable picture of the true natural history.[250]  It must be acknowledged, however, that although incident registries likely provide the best representation of survival for the cohort as a whole, registries based on large numbers of prevalent cases may provide extremely useful prognostic information for a previously diagnosed individual. 
5.5.3 Predictors of survival
CI and WHO functional class are commonly described predictors of survival in PAH and CTEPH however only in recent cohorts as mean age at diagnosis has risen, has the impact of age on prognosis been appreciated. ADDIN EN.CITE [54, 56]  Given the significant increase in the proportion of older patients in current clinical practise, it is important to account for age in comparison of contemporary survival. In addition to age, we have demonstrated for the first time that PH diagnostic group predicts outcome and that these commonly described variables that predict survival also hold true for PH-lung and PH-LHD patients referred to a specialist centre. 
5.5.4 Study Limitations
Many of the limitations of this study are discussed in section 3.11.  The main limitation of this study is its observational nature involving retrospective collection of data from a single centre.  This means that we cannot confidently ascribe causes to the improvement in survival seen compared with historical series.  Also, over the time course of this study changes in disease recognition and treatment modalities occurred.  Outcomes after PEA surgery to disobliterate the pulmonary arterial bed are known to be associated with surgeon and centre experience.[415]  The use of a single national centre for PEA surgery standardises surgical therapy for CTEPH patients as far as possible.  However, over the time period of this study, the learning effect that is well recognised in PEA programmes worldwide may have impacted on outcome of patients undergoing PEA. 
5.5.5 Conclusion
In conclusion, this registry describes survival for a large cohort of consecutive, treatment-naïve patients referred for evaluation of suspected PH at a specialist PH centre. Outcomes in contemporaneous patients with PAH and CTEPH differed depending on diagnostic subgroup and within CTEPH, on surgical intervention.  This study also demonstrates the poor outcome in increasingly recognised subgroups of PH-LHD and PH-Lung who are a focus of active research.  Accurate classification of pulmonary vascular disease by systematic assessment not only informs management but also provides prognostic information.  Although survival has improved in the modern treatment era in patients with PAH and CTEPH, for many patients the outcome remains unacceptably poor.


















Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease

This chapter is largely based on a paper published in the European Respiratory Journal “Pulmonary hypertension in COPD: Results from the ASPIRE registry” Hurdman, J et al Eur Resp J, 2013 41(6);1292-301


Chapter 6: Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease
6.1 Summary	
Rationale: The phenotype and outcome of severe PH in COPD is described in small numbers and predictors of survival are unknown.  
Objectives: To investigate the survival and prognostic factors of PH-COPD and assess the effect of treatment with pulmonary vascular therapies.
Methods: Data was retrieved for 101 consecutive, treatment-naïve cases of PH-COPD diagnosed at the Sheffield Pulmonary Vascular Disease Unit between 1st February 2001 and 1st February 2010 using a cardiac catheter-based approach. 
Results: Mean follow-up was 2.3(±1.9) years.  Fifty-nine patients with COPD and severe pulmonary hypertension, defined by catheter mean pulmonary artery pressure ≥ 40mmHg, had significantly lower carbon monoxide diffusion, less severe airflow obstruction but not significantly different emphysema CT scores compared to 42 patients with mild-moderate pulmonary hypertension. One and three-year survival for severe pulmonary hypertension at 70% and 33% was inferior to 83% and 55% for mild-moderate pulmonary hypertension. Mixed venous oxygen saturation, carbon monoxide diffusion, WHO functional class and age, but not severity of airflow obstruction, were independent predictors of outcome. Compassionate treatment with targeted therapies in 43 patients with severe pulmonary hypertension was not associated with a survival benefit although improvement in functional class and/or fall in pulmonary vascular resistance >20% following treatment identified patients with improved survival.




The development of PH in chronic lung diseases such as COPD has both functional and prognostic implications. ADDIN EN.CITE [99, 281]  PH-COPD is usually mild to moderate with preserved CO and evolves slowly alongside the progression of lung disease and hypoxaemia.[293]  However, a minority of patients develop severe PH with elevations in PAP which have been described as “out of proportion” to underlying COPD. ADDIN EN.CITE [270, 271]  Hypotheses for the aetiology of this phenotype include greater susceptibility to alveolar hypoxia and/or tobacco smoke ADDIN EN.CITE [416, 417], destruction of the capillary vascular bed[418], inflammatory factors initiating remodelling of the pulmonary vascular bed ADDIN EN.CITE [376, 382, 419], or the coexistence of IPAH in patients with lung disease. ADDIN EN.CITE [270] 	

Severe PH in COPD has been arbitrarily defined by a resting mPAP ≥ 40mmHg and occurs in approximately 1% of patients with chronic respiratory failure related to COPD. ADDIN EN.CITE [270]  The high and increasing prevalence of COPD ADDIN EN.CITE [253, 254, 420] and the substantial consequences of developing severe PH have generated increasing interest in PH-COPD, however in this group the employment of targeted pulmonary vascular therapy, while attractive, remains unproven.[421]

The Sheffield Pulmonary Vascular Disease Unit delivers a supra-regional, adult PH service to a population with a COPD prevalence that is one of the highest in Europe. ADDIN EN.CITE [422]  The aim of this study was to compare the characteristics and outcomes of extensively phenotyped, consecutive patients with PH-COPD diagnosed at our specialist referral centre over a 9 year period.  
6.2.1 Objectives
	To determine the baseline characteristics of patients with mild to moderate compared to severe PH-COPD.
	To analyse outcomes in patients with PH-COPD.
	To describe prognostic markers of patients with PH-COPD.
	To assess whether severe PH-COPD is amenable to pulmonary vascular therapy.
	To assess the safety of targeted pulmonary vascular therapy in PH-COPD with regard to degree of hypoxaemia.
	To assess whether an mPAP of 40mmHg is the optimal level to define those patients with poorer outcome.
6.2.2 Hypotheses
	The characteristics of patients with mild to moderate PH-COPD will differ from those of patients with severe PH-COPD.
	The outcome of patients with severe PH-COPD will be inferior to that of mild to moderate PH-COPD.







Patient selection and data retrieval for the ASPIRE registry has been discussed earlier in chapter 3.  In brief, in the ASPIRE (Assessing the Spectrum of Pulmonary hypertension Identified at a Referral centre) Registry, 1737 consecutive, incident, treatment-naive patients with suspected PH underwent diagnostic evaluation between February 2001-2010. ADDIN EN.CITE [423]  Diagnostic classification was by standard criteria following systematic, multidisciplinary assessment that included echocardiography, detailed blood testing, pulmonary function testing, overnight oximetry, isotope perfusion scanning, HRCT, CTPA, RHC and from 2004 cardiopulmonary MRI (figure 1). [178]  Following this detailed assessment, 101 patients were assigned the diagnosis PH-COPD [Updated clinical classification of pulmonary hypertension (Dana point, 2008) class 3.1] ADDIN EN.CITE [10] and comprise the cohort examined in this study.  All patients underwent RHC in a supine position and PH was defined as mPAP ≥ 25mmHg at rest ADDIN EN.CITE [10] with mild to moderate PH-COPD defined as mPAP ≥ 25 mmHg and <40 mmHg and severe PH-COPD defined by mPAP ≥ 40mmHg. ADDIN EN.CITE [270] 

Date of diagnosis was taken as date of first RHC demonstrating PH.  WHO functional class and pulmonary function tests ADDIN EN.CITE [424, 425] ADDIN EN.CITE  obtained closest to date of RHC were recorded as baseline measures.  Exercise capacity was assessed using distance achieved during the ISWT.[395]    

The census point was date of death or 1st August 2011 in survivors. Mortality status was ascertained via the National Health Service enhanced reporting service death report.  There were no patients lost to follow up.  
6.3.2 COPD and Emphysema
For the purposes of this study PH-COPD refers to patients with COPD as defined by post-bronchodilator FEV1/FVC ratio ≤ 0.7 where airflow obstruction was due to a combination of airway and parenchymal damage, as per NICE guidelines updated 2010[391] or significant emphysema. The degree of emphysema and any co-existing pulmonary fibrosis were assessed using HRCT scan independently evaluated by 2 chest radiologists blinded to clinical data and each other’s findings.  A visual scale based on previous studies ADDIN EN.CITE [270, 398, 399] was used to score degree of parenchymal abnormality in the upper, mid and lower zone of each lung (0=<5%, 1=5-25%, 2=26-50%, 3=51-75%, and 4=76-100%) for both emphysema and fibrosis.  In order to assess the distribution of parenchymal disease on HRCT for the purpose of this study, the sum of the right and left upper zone scores was compared to the sum of the right and left lower zone scores for emphysema and fibrosis respectively.  CT acquisition parameters are detailed in section 3.3.5.1.  The main pulmonary artery, ascending aorta, both ventricles and the left atrium were measured as described in section 3.3.5.2.2.
6.3.3 Therapy
The management of COPD was in accordance with contemporaneous guidelines. ADDIN EN.CITE [253, 275, 391, 426]  Pulmonary vascular therapy was used on a compassionate basis in severe PH-COPD with prior agreement from funding bodies as per United Kingdom national commissioning policy.[167, 400]  ERAs, PD-5-Is and prostanoids were used as monotherapy or in combination as clinically indicated.  
6.3.4 Statistical analysis




6.4.1 Demographics and baseline characteristics











Figure 21 Diagnostic pathway

6.4.2 Mild to moderate PH-COPD and Severe PH-COPD
In 42 patients, PH was mild to moderate (mPAP 25-39mmHg) and in 59 PH was severe (mPAP  40mmHg).  In those with severe PH there was haemodynamic evidence of impaired cardiac function with elevated right atrial pressure, reduced cardiac index and mixed venous oxygen saturations (table 17).  The phenotype of severe PH-COPD was also characterised by greater impairment of gas exchange, despite better preserved spirometry but no statistically significant difference in the severity of emphysema on HRCT scan.  Oxygen saturations at rest on room air were significantly lower in those with severe PH-COPD (p <0.001) but this hypoxaemia was adequately corrected, albeit requiring higher flows of long term oxygen to achieve this.  Eight patients with severe PH-COPD had PCWP >15mmHg but there was no difference in the prevalence of cardiac comorbidities when comparing the group with elevated PCWP to those with PCWP ≤ 15mmHg.  In addition, the mean left atrial size (maximum anterior-posterior diameter) on CT scan in patients with PCWP ≤ 15mmHg at 3.6±0.9cm was not significantly different to 3.5±0.8cm seen in patients with elevated wedge (p=0.749). 

Overall on HRCT scan, 43 patients had no evidence of pulmonary fibrosis.  Emphysematous change was more marked in the upper zones compared to the lower zones whereas if a degree of fibrosis was noted this was more prominent in the lower zones (Wilcoxon, p both <0.001).  Difference in overall HRCT scores for emphysema or fibrosis between those with mild to moderate versus severe PH-COPD did not reach statistical significance (table 17).

Table 17 Baseline characteristics in PH-COPD














Left ventricular hypertrophy (%)	7	8	0.807
Ischaemic heart disease (%)	26	39	0.180
Valvular left heart disease (%)	12	7	0.373
Peripheral vascular disease (%)	5	14	0.145
Chronic kidney disease (%)	10	14	0.537
Exercise Limitation			
WHO III/IV (%)	74/12	61/36	0.016
ISWD (m)*	140 (45, 195)	40 (18, 100)	0.001
SpO2 on air (%)	87.86.9	80.59.3	<0.001






Entrained Oxygen flow (L/min)	2.7±1.8	5.3±3.9	0.017
PaCO2 (mmHg	46.5±16.5	34.5±8.3	0.005
PaO2 (mmHg)	72±18	66.8±14.3	0.331
Right Heart Catheter 			
Resting SpO2 at RHC (%)	934	944	0.342













Total Emphysema Score*	5 ( 1, 15)	9.5 (2, 18)	0.191
Total Upper Zone Emphysema* 	3.5 (0, 6)	5.5 (1, 7)	0.214
Total Lower Zone Emphysema*	0 (0, 3)	0.5 (0,4)	0.178
Total Fibrosis Score*	0 (0, 2)	0 (0, 2.5)	0.509
Total Upper Zone Fibrosis* 	0 (0, 0)	0 (0, 0)	0.790
Total Lower Zone Fibrosis*	0 (0, 1.5)	0 (0, 2)	0.330
Pulmonary Artery : Aorta 	1.0±0.1	1.0±0.1	0.202
Right Ventricle : Left Ventricle	1.1 ±0.4	1.3±0.4	0.031
			




Estimated sPAP measured at ECHO correlated weakly with sPAP directly measured at RHC (r=0.54, p<0.01).  In 61% of patients estimated sPAP on ECHO differed from measured sPAP at RHC by >10mmHg. There were weak correlations between mPAP and the pulmonary artery and aortic diameter ratio, right ventricular and left ventricular diameter ratio measured on CT-scan and TLco (r=0.17, 0.29 and 0.39, respectively,  p all <0.05).
6.4.4 Survival and prognostic indicators




Figure 22 Cumulative survival from date of diagnosis in pulmonary hypertension associated with COPD by mPAP


     42     35    21     12      8      6	      PH-COPD mPAP 25-39mmHg
 	     59     41    21     13      8      7	      PH-COPD mPAP ≥ 40mmHg
   	   101     76    42     25    1      13	      Total 







Table 18 Cox regression survival analysis to assess predictors of survival in pulmonary hypertension associated with COPD

	Univariate HR	p value	Multivariate HR	p value
				




BMI (kg/m2)	0.958 (0.922, 0.996)	0.029		
WHO 				
III	Reference		Reference	
IV	2.471 (1.421, 4.296)	0.002	0.485 (0.249, 0.943)	0.033
ISWD (m)	0.996 (0.993, 0.999)	0.011		
Haemodynamics				
mRAP (mmHg)	1.034 (0.980, 1.091)	0.225		
mPAP (mmHg)	1.034 (1.011, 1.057)	0.003		
CI (L.min.m-2)	0.481 (0.331, 0.699)	<0.001		
PCWP (mmHg)	0.945 (0.893, 0.999)	0.047		
PVR (dyn.s.cm-5)	1.001 (1.001, 1.002)	<0.001		
SvO2 (%)	0.918 (0.887, 0.950)	<0.001	0.947 (0.910, 0.986)	0.008
HRCT Scores				
Total Emphysema	1.047 (1.008, 1.088)	0.018		
Total Fibrosis	1.034 (0.956, 1.119)	0.407		
PFTS				
FEV1 (% predicted)	1.011 (1.001, 1.025)	0.006		
FVC (% predicted)	1.011 (1.001, 1.022)	0.039		
TLco (% predicted)	0.964 (0.946, 0.982)	<0.001	0.975 (0.954, 0.996)	0.020
				
Abbreviations as table 17
Figure 24 Cumulative survival from date of diagnosis in pulmonary hypertension associated with COPD by ROC curve-derived threshold of age at diagnosis


       62     51     31     19     13     10         Age <73 years
      39      25     11       6       3       3   	Age >73years





Figure 25 Cumulative survival from date of diagnosis in pulmonary hypertension associated with COPD by ROC curve-derived threshold of TLCO at diagnosis


        48     41     27    18     13     10       		TLco >27%
        45     31     12      7       3       3       		TLco <27%
        93     72     39    25     16     13 		Total    


Figure 26 Cumulative survival from date of diagnosis in pulmonary hypertension associated with COPD by ROC curve-derived threshold of SvO2 at diagnosis


        51     43      27     16     11      10		SvO2 >65%
        47     30      13       7       3        1		SvO2 <65%
  	        98     73      40     23     14      11		Total


Figure 27 Cumulative survival from date of diagnosis in pulmonary hypertension associated with COPD by WHO functional class at diagnosis


 	       67     52     35    21    14      12       	WHO functional class III
      26      17       3      2      1        1       	WHO functional class IV
      93      69     38    23    15      13      	Total


6.4.5 Treatment in PH-COPD
Forty-three patients with severe PH-COPD were treated compassionately with pulmonary vascular therapies; first line treatment was with PDE-5-I in 31 patients, ERA in 10 patients, subcutaneous treprostinil in 1 patient and nebulised iloprost in 1 patient (table 19). All patients received targeted pulmonary vascular therapy for at least three months unless death occurred before this time. In the group of patients with severe PH-COPD survival for the 43 treated patients was similar to the 16 untreated patients (figure 27), despite pulmonary haemodynamics being significantly worse in those disproportionate patients receiving therapy (table 20). For the purposes of this study, clinical improvement was defined as a fall in PVR >20% or improvement in WHO functional class. At follow-up, RHC data was available for 7 patients and showed >20% reduction in PVR in 4 patients. A further 4 patients experienced an improvement in WHO functional class after 4±2 months of treatment. The 8 patients who demonstrated clinical improvement had superior survival when compared to the 35 patients receiving pulmonary vascular treatment without objective improvement (figure 28) even though there was no significant difference in demographics, haemodynamic severity, PFTs or HRCT scan scores between the 2 groups.  





Table 19 Therapy in patients with PH-COPD 

	COPD mPAP 25-39mmHg	COPD mPAP ≥ 40mmHg
	n=42	n=59













Maximal PH Therapy (%)		
   None	83.4	27.1
   Oral monoRx 	14.3	64.4
   Oral comb	0	5.1
   Prostanoid monoRx	0	1.7
   Prostanoid comb	2.4	1,7
Abbreviations see table 8; LABA, long acting beta agonist.


Figure 28 Cumulative survival from date of diagnosis in patients with pulmonary hypertension associated with COPD and mPAP ≥ 40mmHg by use of pulmonary vascular treatment 


     16     10       6       4       3       3   No pulmonary vascular therapy
     43     31     15       9       5       4   Treated with pulmonary vascular therapy





Table 20 Characteristics of patients with pulmonary hypertension associated with COPD and mPAP ≥ 40mmHg by treatment group








ISWD (m)*	40 (15, 120)	55 (33, 100)	0.616
Right Heart Catheter 			
Entrained O2 at RHC (L/min)*	3.0 (0, 5.5)	2.0 (0, 5.3)	0.439












Total Emphysema Score*	9 (2, 18.3)	10.5 (1.9, 15.7)	0.876
Total Fibrosis Score*	0.5 (0, 3.3)	0 (0, 1.5)	0.199
			
Abbreviations as table 17.  Mean (± standard deviation) and p value refers to independent t-test unless indicated with * where for nonparametric data Mann-Whitney U test was used and results expressed as median (interquartile range).
Figure 29 Cumulative survival from diagnosis in patients with pulmonary hypertension associated with COPD and mPAP ≥ 40mmHg by features of response to pulmonary vascular treatment (improvement in WHO functional class or fall in pulmonary vascular resistance >20%) compared to those without response

 	       8        8       4      2       2        2	Respond to therapy
     35      23     11      7       3        2         	No PVR or WHO FC response to therapy




This study describes several important observations regarding the largest cohort of patients with severe PH-COPD yet studied. Firstly, we have confirmed a phenotype of markedly reduced gas transfer, greater hypoxaemia despite less pronounced airflow obstruction when compared to those with mild-moderate PH-COPD. ADDIN EN.CITE [270, 271]  In addition we have demonstrated significantly worse WHO functional class and exercise capacity in severe PH-COPD with a poor prognosis and a disease trajectory that is significantly worse than patients with mild-moderate PH-COPD. ADDIN EN.CITE [271, 284] 

While SvO2 has prognostic value in unselected patients with COPD[427], independent prognostic markers in patients with PH-COPD have not previously been described.  We have identified age, TLco, SvO2 and WHO functional class as independent predictors of survival in PH-COPD.  Although an mPAP ≥ 40mmHg is traditionally used to define those with severe PH-COPD, SvO2 ≤ 65% and TLco ≤ 27% are perhaps better thresholds to define poor outcome in PH-COPD.  It is interesting to note, however, that an mPAP of 40 mmHg, the traditionally used threshold for describing severe PH-COPD, was in fact the optimal mPAP value derived by ROC curve analysis of subsequent survival.  These important parameters have utility in counselling patients regarding prognosis.  In addition, while in mild-moderate PH-COPD, exercise capacity is limited by exhaustion of ventilatory reserve[428], mPAP ≥ 40mmHg has recently been shown to characterise patients with PH-COPD who have an exhausted circulatory reserve on exercise. ADDIN EN.CITE [429]  

Patients with severe PH-COPD were more hypoxaemic on room air and more hypocarbic, presumably the latter reflecting hyperventilation to improve oxygenation.  Interestingly, although hypoxaemia was adequately corrected by long term oxygen therapy, severe PH persisted.  These observations support the hypothesis that hypoxia is not the sole driver of severe PH-COPD. ADDIN EN.CITE [281, 292]  

There is little data supporting the use of pulmonary vasodilators used in PAH in patients with PH-COPD. ADDIN EN.CITE [430-433]  However, there is growing interest in considering RCTs in this population given the pulmonary haemodynamic characteristics of these patients.  In the present study, patients with severe PH-COPD who received compassionate treatment with targeted pulmonary vasodilator therapy had a very poor outcome with a one year survival of 72% which was not significantly different to those who did not receive targeted therapy (63%, p=0.672), although the treated group had more severe pulmonary haemodynamics. The lack of a demonstrated survival benefit, however, does not necessarily confirm a lack of efficacy, but does suggest that with current targeted therapies the outcome for the group as a whole remains poor. Mechanisms suggested to contribute to the severe haemodynamic change seen in patients with severe PH-COPD include destruction of the capillary vascular bed or the development of a vasculopathy. ADDIN EN.CITE [270, 271]  Interestingly, the 19% of patients with severe PH-COPD identified arbitrarily as having an objective response to therapy based on improvements in WHO functional class or >20% fall in PVR had a superior survival compared to non-responders and may represent a phenotype in which there is a greater degree of potentially treatment-responsive vasculopathy compared to emphysematous obliteration of the pulmonary microvascular bed.  Although these observations are based on small numbers they do raise the possibility that a proportion of patients with PH-COPD may derive benefit from targeted therapies and support further investigation in the context of RCTs.  A previous study raised concerns regarding acute worsening of oxygen saturation in patients with modest PH-COPD but more severe airflow obstruction receiving a dose of sildenafil. ADDIN EN.CITE [430]  In the current study no clinically significant worsening of oxygen saturations was observed acutely in patients receiving sildenafil although these results should be treated with caution as this study was not primarily designed to assess this effect.  Importantly, we have identified markers of disease severity in PH-COPD which may be helpful in defining patient groups for further study and given the extremely high observed mortality, survival may be an appropriate endpoint in such studies.  While the utility of exercise testing as an end-point in PH-COPD cannot be ascertained from this study, at follow-up visits patients were frequently unable to perform exercise testing suggesting its value may be limited. 

We have recently also shown the importance of accurate phenotyping of patients with PH with multi-modality assessment including imaging and cardiac catheterisation and that classification predicts outcome. ADDIN EN.CITE [423]  A significant number of patients with severe PH-COPD had spirometric values which would have allowed entry into RCTs of therapies for IPAH and would have met registry criteria for IPAH ADDIN EN.CITE [11] despite having severe emphysema. This observation emphasises the importance of HRCT assessment of lung parenchyma in those with RHC parameters suggestive of IPAH.  In the ASPIRE registry, patients who clearly had CFES were classified as having PH-Lung secondary to mixed obstructive and restrictive defects and were not enrolled in the current study.  On further detailed quantitative radiological evaluation for the purposes of this study (not available at the time of initial classification) 2 patients with a diagnosis of PH-COPD did have more significant elevation of fibrosis scores. However, emphysema scores for both of these patients were greater than their fibrosis scores. The vast majority of patients otherwise had no or minimal fibrosis and when present its extent was not significantly different between the mild to moderate PH-COPD and severe PH-COPD groups. 

In this study, patients were catheterised in clinical stability outwith exacerbations which are associated with significant rises in mPAP.[341]  Non-invasive measures in these patients did not correlate reliably with mPAP at RHC, as described elsewhere. ADDIN EN.CITE [288]  This compounds the difficulty in distinguishing patients with severe PH-COPD from patients with severe COPD without PH and emphasises the importance of cardiac catheterisation where knowledge of the patient’s pulmonary vascular status is important.  The presence of features of the phenotype of severe PH described here and elsewhere ADDIN EN.CITE [270], such as a very low TLco or severe hypoxaemia in the setting of relatively well preserved spirometry can raise suspicion, although thorough investigation is required to characterise these patients and exclude other causes of PH and is best performed at specialist centres, through which RCTs of therapies may be co-ordinated.[292]

COPD is a systemic disease and the BODE index recognises BMI in addition to markers of reduced respiratory reserve, namely FEV1, MRC dyspnoea score and exercise capacity as important prognostic markers.[253] ADDIN EN.CITE   In the current study functional class, as well as age at diagnosis and measures of gas transfer and cardiac function were shown to independently predict survival, but importantly FEV1, BMI and exercise capacity did not.  This implies conventional COPD prognostic models may not apply in patients with PH-COPD. This is noteworthy in view of the increasing interest in the accurate phenotyping of distinct subgroups of patients with COPD. 
6.5.1 Study Limitations
Many of the general limitations of this study are discussed in section 3.11.  The population studied represents a highly selected cohort of patients referred to a supra-regional PH referral centre in whom the elevation in PAP was thought to be out of proportion to the severity of underlying respiratory disease.  Therefore no estimate of the incidence or prevalence of PH-COPD in the COPD population can be drawn from this study.  Also, despite the routine use of HRCT scan in diagnostic evaluation, HRCT films were unavailable for scoring for 27 patients. However, pulmonary function did not significantly differ in the group with and the group without CT films available for scoring. Furthermore, the clinical reports of HRCT were consulted as part of data collection to confirm patients did not have significant pulmonary fibrosis.  A small number of patients in whom COPD was the clear cause for PH, but who had elevations in PCWP without increased prevalence of cardiovascular morbidity, were included in the cohort. In these patients left heart disease was not thought to be the cause of pulmonary hypertension and indeed the left atrial size was usually normal in these patients.  While left ventricular diastolic impairment has a prevalence in some studies of 90% in patients with severe stable COPD[434], the majority of patients in this cohort did not have severe airflow obstruction.  In addition gas trapping with elevated intrathoracic pressures may be an alternative explanation for increased PCWP in patients with COPD. ADDIN EN.CITE [273]
6.5.2 Conclusion 


















Chapter 7 Conclusion and Outlook
Patient registries are a useful source of data about patients with rare conditions.  In order to advance therapeutic strategies and ultimately improve survival, an understanding of the characteristics and contemporary outcomes across the diagnostic classification of PH is required.  To date, the ASPIRE registry is the largest, single centre registry of consecutive cases of PH spanning the clinical spectrum encountered in the developed world.  Importantly, in the APSIRE registry, all cases were incident, treatment-naïve, unselected and diagnosed by a catheter-based approach.  The ASPIRE registry has facilitated comparison between diagnostic groups and subgroups and demonstrated the importance of accurate phenotyping and the implications of classification for survival. 

Many of our findings regarding PAH & CTEPH concur with those previously described suggesting our cohort is representative of the population seen at specialist PH centres in Europe and the USA. ADDIN EN.CITE [11, 31, 55, 238, 246]  There was a marked difference in survival between the 3 commonest forms of Group 1 (Eisenmenger’s, IPAH and CTD-PAH).  Although patients with PAH are classified together in Group 1, an appreciation that characteristics and outcomes differ between subgroups is crucial and has lead to a conceptual shift in PAH research over recent years.[435]  Survival in PAH-SSc is inferior to that of IPAH ADDIN EN.CITE [29, 239, 413] and PAH-SSc appears to be less responsive to targeted pulmonary vascular therapies than IPAH[436]; IPAH and PAH-SSc are not equivalent diseases. ADDIN EN.CITE [112, 113, 411, 437]  Accounting for this in clinical trials is the key to deriving maximal benefit from therapies and making progress towards improved outcomes for each individual disease subgroup.  

7.1 The importance of accurate classification
Our results highlight the need for precise classification of pulmonary vascular disease to inform management and prognostication.  This requires thorough, systematic evaluation of patients with severe unexplained PH by expert practitioners, particularly assessment with RHC and appropriate radiology.  This is crucial to ensure patients with PH-LHD or PH-Lung are not misclassified as IPAH.  Similarly, in patients with CTD, the type of PH must be defined as this influences therapeutic strategy and prognosis.  Furthermore, for the first time we have shown that in CTEPH, patients with operable disease who underwent PEA had the best long-term outcome.  This emphasises the role of imaging in the effective identification of patients with potentially operable CTEPH particularly as haemodynamic features may be indistinguishable from those with surgically inaccessible disease. 

In order to compare and contrast patient registries, precise case definitions are required.  The most recent diagnostic classifications of PH are not sufficiently descriptive of the definitions that should be applied to the often complex and dynamic underlying diseases associated with PH. ADDIN EN.CITE [6, 438]  Furthermore, RHC criteria alone are inadequate in the definition of diagnostic group in the current era of advanced imaging modalities as shown by the increasing recognition of patients with IPAH who do not meet traditional PCWP criteria.[56]  
7.2	Groups 2 & 3 

The acknowledgement that patients with PH-LHD and PH-Lung in the ASPIRE registry are subject to selection bias and are not representative of the general population with cardio-respiratory diseases, implies that these patients represent a highly selected population referred due to suspected PH out of proportion to their underlying heart or lung disease.  The recognition that PH negatively impacts survival in lung and left heart disease and the desire to utilise therapies that target the pulmonary vasculature in PH-LHD and PH-Lung, has concentrated interest on these patients where the distinction between proportionate and disproportionate PH is crucial.  Importantly, our findings provide prognostic information to inform clinicians counselling patients with more severe pulmonary hypertension in the context of left heart disease and lung disease.  

Right ventricular dilatation, hypertrophy and ultimately impairment are common in patients with chronic lung disease even prior to elevation in PAP and the development of PH. ADDIN EN.CITE [377, 439]  While the prevalence of PH-COPD increases with increasingly severe airflow obstruction ADDIN EN.CITE [440], it is important to recognise the rare phenotype of PH out of proportion to underlying lung disease where features similar to those seen in IPAH dominate the clinical picture.  The ASPIRE registry contains the largest cohort of patients with severe PH-COPD yet studied.  This study has confirmed a phenotype of markedly reduced gas transfer, greater hypoxaemia despite less pronounced airflow obstruction when compared to those with mild-moderate PH-COPD. ADDIN EN.CITE [270, 271]  In addition, patients with severe PH-COPD have very poor prognosis and our data supports the concept that patients with mild-moderate lung disease but severe PH may exhibit a clinical response to pulmonary vascular therapies used in PAH.  RCTs addressing morbidity and mortality endpoints are needed to assess the efficacy and long term safety of pulmonary vascular therapy in patients with PH-Lung.  This is a rapidly evolving area and since this study was undertaken new treatments such as Riociguat, a soluble guanylate cyclase stimulator, have show promise in patients with PH-Lung. ADDIN EN.CITE [441]
7.3 Predicting survival
Given the invasive and time-consuming nature of RHC, it is not ideally suited to monitoring disease course and response to therapy.  Therefore various surrogate markers have been adopted.  CI and WHO functional class are commonly described predictors of survival in PAH and CTEPH.  However, only in recent cohorts, as mean age at diagnosis has risen, has the impact of age on prognosis been appreciated. ADDIN EN.CITE [54, 56]   In addition to age, we have demonstrated for the first time that PH diagnostic group predicts outcome and that commonly described variables that predict survival also hold true for PH-lung and PH-LHD patients referred to a specialist centre. 

In the general COPD population, FEV1 is a strong predictor of survival. ADDIN EN.CITE [422]  Conventional COPD prognostic models such as the BODE index ADDIN EN.CITE [442] may not apply in patients with PH-COPD.  We have shown that patients referred to a specialist centre with PH-COPD have a poor prognosis that can be best predicted by age, functional status and markers of gas exchange and transport, but not by FEV1.  
7.4	Outcomes

Prior to the availability of targeted pulmonary vascular therapy, patients with PAH had high mortality rates.  Over the past 2 decades, there have been major advances in clinical management, the quality of imaging used to diagnose and monitor PH and the development of new therapies. In the ASPIRE registry, observed survival in IPAH was markedly improved compared to that predicted by the NIH equation, even in the younger patient group (<50 years) with an age range more akin to that in the early registries ADDIN EN.CITE [91], suggesting a true improvement in mortality.  

The challenges of achieving early diagnosis and effectively screening high risk patient groups remain.  As seen in other registries, there was a high degree of functional impairment at baseline suggesting delay in diagnosis which is known to impinge on survival. ADDIN EN.CITE [11, 91]  Early diagnosis requires a high level of suspicion among healthcare professionals for rare conditions such as PAH and CTEPH.  PH should be considered in all patients presenting with dyspnoea in the absence of a clear alternative cause.[32]

To facilitate further improvements in survival using present forms of therapy, sub-group specific, goal-orientated therapy based on measures that reflect right ventricular function may be superior to standard clinical management strategies.  Moreover there is a growing appreciation of the need to ascertain the optimal combinations of therapies.  In subgroups with dismal prognosis, such as severe PH-COPD, death can clearly be used as an endpoint.  In other subgroups, appropriate, validated and clinically meaningful surrogate end-points are required.  The value of biomarkers combined with imaging parameters from the rapidly developing fields of ECHO and Cardiac MRI await assessment across populations regarding their sensitivity to prognosis and therapeutic interventions. Biobanks collecting patient serum and tissue samples in conjunction with clinical data are likely to form the registries of the future, resulting in a multidimensional approach to tracking disease trajectory.  Ultimately, treatment-specific biomarkers may optimise selection of individualised treatment and monitor response to therapy.[443]  

7.5	The role of specialist pulmonary vascular centres
In the United Kingdom, nationally designated healthcare services for PH aim to ensure all patients may access specialist assessment and promptly receive appropriate therapy.  PH specialist services have increasing number of patients on targeted therapy as survival improves, more patients receive a diagnosis of PH and the indications for targeted therapies expand.[12]  Regular reassessment of parameters with proven prognostic importance at PH specialist centres and the co-ordination of shared-care across healthcare networks is central to management.  To afford continued progress in the development of effective therapies, specialist PH centres must work in collaboration participating in well-designed clinical trials.  This is particularly crucial in patients with PH out of proportion to left heart or lung disease and in the evaluation of the optimal combinations of therapies in individual disease subgroups where RCTs are unlikely to be undertaken and review of clinical experience in patient cohorts is the best alternative.

Although lower treatment costs are imminent, the prescription of targeted pulmonary vascular therapy should follow methodical, detailed investigation and expert review to identify the diagnostic subgroup.  This prevents indiscriminate use or harmful misuse of targeted pulmonary vascular therapies for example in patients with left heart disease.  Also as we have shown, diagnostic classification informs prognosis which facilitates counselling of patients and palliative strategies to be employed appropriately.

7.6	Screening for pulmonary hypertension
PH specialist centres also work in partnership with CTD services to raise awareness of this condition and emphasise the importance of consistent screening programmes.  Studies suggest that targeting high risk populations such as patients with SSc through screening programmes will facilitate earlier diagnosis at a time of milder disease. ADDIN EN.CITE [33, 132]  Our screening programme was associated with a more than five fold increase in patients evaluated and diagnosed with PH but disappointingly no improvement in haemodynamic severity at diagnosis was seen.  

In patients with lung disease, the inaccuracy of ECHO as an initial screening investigation contributes to the difficulty of identifying the few patients with severe or disproportionate PH in whom further assessment is advisable.  ADDIN EN.CITE [129, 334] 
7.7	Study Limitations
As discussed, the main limitation of this study is its single centre, observational nature.  Therefore, improvements in survival cannot be attributed to a specific cause, although in keeping with the literature, the APSIRE registry demonstrates improved outcomes compared to historical series and supports the view that survival is improved by the timely introduction of modern therapies. A further limitation of this study is the lesser number of patients in some subgroups and larger studies are required to further define the characteristics and outcomes of these groups.  This is particularly pertinent in subgroups such as PAH-HIV where global prevalence of the underlying disease is high.

General applicability may be reduced in a single centre registry but there was high concurrence between our findings and comparable contemporary registries.  In addition, the ASPIRE registry exhibits the strengths of a single centre registry namely, exhaustive interrogation of patient records enabling excellent data completeness and a standardised investigative and management strategy.   Survivor bias was negated by using unselected cases that were truly incident rather than statistical techniques to adjust for prevalent cases. 

Acknowledging the limitations of registry data, when taken in context the ASPIRE registry provides a valuable data source regarding the characteristics and outcomes of a “real world” patient population.   The detailed phenotypic and outcome data are required to refine patient selection and endpoints for future RCTs and ultimately allow the development of more effective therapeutic strategies.

7.8	Hypotheses & emerging questions
The ASPIRE registry has addressed the hypotheses set out in chapters 1 and 2.  However, this work is hypothesis generating and numerous questions remain unaddressed and merit further attention.  For example;  

	The reasons behind poorer outcomes in older patients with IPAH remain unclear
	The impact of parenchymal lung disease in addition to a pulmonary vasculopathy is significant as evidenced by patients with PH-COPD and PH-ILD but also starkly demonstrated by the poor survival in patients with PH-CTD-Lung compared to patients with CTD without significant lung disease.  The interactions between lung parenchyma and the pulmonary vasculature need to be better understood. 
	The natural history of the group of patients with mPAP 21 to 24mmHg inclusive is undefined
7.9	In conclusion 
To conclude, the ASPIRE registry describes survival for a large cohort of consecutive, treatment-naïve patients referred for evaluation of suspected PH at a specialist PH centre. Outcomes in contemporaneous patients with PAH and CTEPH differed depending on diagnostic subgroup and within CTEPH, on surgical intervention.  This registry also demonstrates the poor outcome in increasingly recognised subgroups of PH-LHD and PH-Lung who are a focus of active research.    



















Appendix - Potential Biomarkers in Pulmonary Hypertension 
8.1 Troponin
Troponin is a specific marker of myocyte injury and detectable serum cardiac troponin levels in patients with chronic PAH are an independent marker of increased risk of mortality. ADDIN EN.CITE [117]
8.2 Uric Acid
Uric acid, the end result of purine metabolism, is increased in hypoxic states, is increased in proportion to severity of IPAH and is an independent prognostic marker in IPAH.[118]
8.3 Brain natriuretic peptide
Brain Natriuretic Peptide (BNP) release is mainly triggered by volume overload and wall stretch in the atria and ventricles. ADDIN EN.CITE [444, 445]  Levels correlate with moderate to severe PH ADDIN EN.CITE [119, 120] and mirror changes in right heart structure and function on MRI scan. ADDIN EN.CITE [121]  BNP is a predictor of mortality, disease progression and response to therapy in PAH and CTEPH ADDIN EN.CITE [120, 446, 447] but BNP is unlikely to offer early or latent PH diagnosis.[353]  Studies are needed in unselected patient groups where possible confounding factors such as left heart disease and renal failure are included. ADDIN EN.CITE [448]
8.4 Endothelin 1
Endothelin 1 levels correlate with haemodynamic characteristics including PVR, mPAP and CI and has been suggested as a potential parameter for detecting PH in SSc. ADDIN EN.CITE [449]

8.5 CA-125
CA-125 levels increase in proportion to degree of right ventricular failure seen on ECHO in patients with COPD. ADDIN EN.CITE [450]  
8.6 Osteoprotegerin & OPG:TRAIL ratio
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Standard Panel of Investigations for ASPIRE Registry
ECG, ECHO, PFTs, ISWT, CXR, CTPA, HRCT, Cardiopulmonary MRI*, isotope lung scan, overnight pulse oximetry, panel of blood tests, right heart catheterisation and other investigations as deemed clinically required to elicit underlying diagnoses eg liver USS, TOE


Multi-disciplinary meeting with specialist pulmonary vascular clinicians and radiologists

Opinions from other specialties as required














Review of diagnosis by single investigator (JH)

Standard Panel of Investigations for ASPIRE Registry
ECG, Echocardiogram, PFTs, ISWT, CXR, CTPA, HRCT, Cardiopulmonary MRI*, isotope lung scan, overnight pulse oximetry, panel of blood tests, right heart catheterisation 


Multi-disciplinary meeting with specialist pulmonary vascular clinicians and radiologists








Group 1     n=600
Group 2     n=157
Group 4     n=242
Group 5     n=32




Group 3 PH associated with lung disease

COPD			      n=101
ILD			      n=32
Mixed Deficit		      n=18
Sleep Disorders	      n=10






mPAP ≥ 40mmHg 		n=59













52 CTEPH not operated





218 patients with CTEPH included

20 patients awaiting PEA at census date excluded

4 patients excluded with uncertain disease distribution
















^1	  This classification was in place at the time of this study and was superseded in 2013 by a further updated clinical classification of pulmonary hypertension produced at the 5th World Symposium. ADDIN EN.CITE  ADDIN EN.CITE.DATA [13] 
^2	  ALK1 = Activin receptor-like kinase type 1BMPR2 = bone morphogenetic protein receptor type 2
^3	  DLco in figure 2 is an alternative abbreviation for TLco.
^4	  A plexiform lesion is a focal proliferation of endothelial channels lined by myofibroblasts, smooth muscle cells and connective tissue matrix, often located at an arterial branching point and within the pre and intra-acinar pulmonary arteries.  This is the hallmark of obstructive intimal remodelling [8]. 
^5	  Modified Bernoulli equation Estimated RVSP = 4V2 + estimated right atrial pressure, where V is the velocity of the tricuspid jet.
^6	  Cardiac output may be measured by thermodilution or, if oxygen consumption is measured, it may be calculated using the Fick method.
^7	  The updated guidelines for the management of pulmonary hypertension published in 2013 restrict this recommendation to patients with IPAH. ADDIN EN.CITE  ADDIN EN.CITE.DATA [173]
^8	  For the latest guidance on targeted pulmonary vascular therapies, please refer to The Updated Treatment Algorithm of Pulmonary Hypertension published in 2013 ADDIN EN.CITE  ADDIN EN.CITE.DATA [173].
^9	  Targeted pulmonary vascular therapy was not available in China during the time period of this study.
^10	  Patients with porto-pulmonary hypertension, PAH-CTD and familial PAH were shown to have an increased hazard ratio. 
^11	  Hypercapnea causes increase in proximal renal reabsorption of bicarbonate to minimize the fall in arterial PH.  This in turn promotes passive reabsorption of sodium chloride and water. [[260] ADDIN EN.CITE <EndNote><Cite><Author>Neylon</Author><Year>1995</Year><RecNum>208092</RecNum><record><rec-number>208092</rec-number><foreign-keys><key app="EN" db-id="xxvd59z5za0adeefzr2xxsfip292trt0tw9t">208092</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Neylon, M.</author><author>Marshall, J. M.</author><author>Johns, E. J.</author></authors></contributors><auth-address>Department of Physiology, Medical School, Birmingham, UK.</auth-address><titles><title>The effects of systemic hypoxia on renal function in the anaesthetized rat</title><secondary-title>J Physiol</secondary-title></titles><periodical><full-title>J Physiol</full-title></periodical><pages>497-511</pages><volume>487 ( Pt 2)</volume><edition>1995/09/01</edition><keywords><keyword>Animals</keyword><keyword>Anoxia/*physiopathology</keyword><keyword>Blood Gas Analysis</keyword><keyword>Denervation</keyword><keyword>Glomerular Filtration Rate</keyword><keyword>Hemodynamics</keyword><keyword>Kidney/innervation/*physiopathology</keyword><keyword>Male</keyword><keyword>Rats</keyword><keyword>Rats, Wistar</keyword><keyword>Sodium/urine</keyword></keywords><dates><year>1995</year><pub-dates><date>Sep 1</date></pub-dates></dates><isbn>0022-3751 (Print)&#xD;0022-3751 (Linking)</isbn><accession-num>8558479</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=8558479</url></related-urls></urls><custom2>1156588</custom2><language>eng</language></record></Cite></EndNote>[261]
^12	  Since the time of study, the definition of severe pulmonary hypertension in lung disease has been refined at the fifth world symposium. ADDIN EN.CITE  ADDIN EN.CITE.DATA [272] 
^13	  In 2011, prevalence of HIV in the UK was 0.14%, in France 0.23% and in USA 0.38%.  In USA 18.5% of cases of HIV were associated with intravenous drug use compared to only 2% in France.
